KR20230040292A - Novel 2-aminobenzothiazole derivatives and preparation method thereof - Google Patents
Novel 2-aminobenzothiazole derivatives and preparation method thereof Download PDFInfo
- Publication number
- KR20230040292A KR20230040292A KR1020220115668A KR20220115668A KR20230040292A KR 20230040292 A KR20230040292 A KR 20230040292A KR 1020220115668 A KR1020220115668 A KR 1020220115668A KR 20220115668 A KR20220115668 A KR 20220115668A KR 20230040292 A KR20230040292 A KR 20230040292A
- Authority
- KR
- South Korea
- Prior art keywords
- trans
- cyclohexyl
- thiazol
- amine
- benzo
- Prior art date
Links
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical class C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 title claims abstract description 118
- 238000002360 preparation method Methods 0.000 title description 4
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 claims abstract description 17
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000026731 phosphorylation Effects 0.000 claims abstract description 16
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 196
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 144
- 239000000203 mixture Substances 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 45
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 28
- -1 2-aminobenzothiazole derivative compound Chemical class 0.000 claims description 22
- 239000000460 chlorine Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- 125000005605 benzo group Chemical group 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 108010044843 Peptide Initiation Factors Proteins 0.000 claims description 7
- 102000005877 Peptide Initiation Factors Human genes 0.000 claims description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 230000014621 translational initiation Effects 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 230000019522 cellular metabolic process Effects 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- BGSRFMFTXMPTSC-UHFFFAOYSA-N 6-fluoro-1,3-benzothiazole Chemical compound FC1=CC=C2N=CSC2=C1 BGSRFMFTXMPTSC-UHFFFAOYSA-N 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 239000003183 carcinogenic agent Substances 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 3
- 230000009702 cancer cell proliferation Effects 0.000 abstract description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 306
- 235000019439 ethyl acetate Nutrition 0.000 description 115
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 78
- 238000005481 NMR spectroscopy Methods 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- 238000003818 flash chromatography Methods 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 39
- 229910000027 potassium carbonate Inorganic materials 0.000 description 39
- 239000000741 silica gel Substances 0.000 description 39
- 229910002027 silica gel Inorganic materials 0.000 description 39
- 239000007787 solid Substances 0.000 description 39
- 238000003756 stirring Methods 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- ISIIQFDYFMPPOA-UHFFFAOYSA-N 2-chloro-6-fluoro-1,3-benzothiazole Chemical compound FC1=CC=C2N=C(Cl)SC2=C1 ISIIQFDYFMPPOA-UHFFFAOYSA-N 0.000 description 10
- KUCSJGBXJBQHNI-UHFFFAOYSA-N 2-chloro-6-nitro-1,3-benzothiazole Chemical compound [O-][N+](=O)C1=CC=C2N=C(Cl)SC2=C1 KUCSJGBXJBQHNI-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- BSQLQMLFTHJVKS-UHFFFAOYSA-N 2-chloro-1,3-benzothiazole Chemical compound C1=CC=C2SC(Cl)=NC2=C1 BSQLQMLFTHJVKS-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- QDZGJGWDGLHVNK-UHFFFAOYSA-N 2,6-dichloro-1,3-benzothiazole Chemical compound C1=C(Cl)C=C2SC(Cl)=NC2=C1 QDZGJGWDGLHVNK-UHFFFAOYSA-N 0.000 description 4
- YIRRVMGAKFESLR-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)-1,3-benzothiazole Chemical compound FC(F)(F)C1=CC=C2N=C(Cl)SC2=C1 YIRRVMGAKFESLR-UHFFFAOYSA-N 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FVUFTABOJFRHSU-UHFFFAOYSA-N 2-chloro-6-methoxy-1,3-benzothiazole Chemical compound COC1=CC=C2N=C(Cl)SC2=C1 FVUFTABOJFRHSU-UHFFFAOYSA-N 0.000 description 3
- BULNNISVPSQIFO-UHFFFAOYSA-N 6-(trifluoromethyl)-1,3-benzothiazole Chemical compound FC(F)(F)C1=CC=C2N=CSC2=C1 BULNNISVPSQIFO-UHFFFAOYSA-N 0.000 description 3
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102100032139 Neuroguidin Human genes 0.000 description 3
- 101710203741 Neuroguidin Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- AIBQGOMAISTKSR-UHFFFAOYSA-N 6-chloro-1,3-benzothiazole Chemical compound ClC1=CC=C2N=CSC2=C1 AIBQGOMAISTKSR-UHFFFAOYSA-N 0.000 description 2
- QLUFBCVWKTWKBF-UHFFFAOYSA-N 6-nitro-1,3-benzothiazole Chemical compound [O-][N+](=O)C1=CC=C2N=CSC2=C1 QLUFBCVWKTWKBF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 2
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AHOIGFLSEXUWNV-UHFFFAOYSA-N 6-methoxy-1,3-benzothiazole Chemical compound COC1=CC=C2N=CSC2=C1 AHOIGFLSEXUWNV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000008211 brain sarcoma Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000009221 stress response pathway Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
Abstract
Description
본 발명은 신규 2-아미노벤조티아졸 유도체 및 이의 제조방법을 제공한다.The present invention provides a novel 2-aminobenzothiazole derivative and a method for preparing the same.
단백질 합성의 조절, 특히 개시단계에서의 조절은 세포의 성장, 증식, 분화 그리고 사멸에 아주 중요한 역할을 한다. 진핵세포에서는 여러 가지의 진핵생물개시인지 (eukaryotic initiation factor; eIF) 가 존재하며, 이는 리보솜 서브유닛 (ribosome subunits), mRNA, 그리고 개시 tRNA (initiator tRNA) 가 적절하게 단백질 합성을 개시하게끔 작용한다. 이런 작용을 위해서는 많은 인자들의 복합체가 단계적으로 결합하여야 한다. 복합체를 이루는 인자 중 대표적으로 eIF4E와 eIF4G가 중요한 역할을 한다. eIF4E와 eIF4G는 비교적 작은 크기의 단백질인 4E-BP (eIF4E-binding proteins) 들에 의해 조절이 된다. 최근 발표된 연구로부터, 4E-BP의 기능을 대신하여 eIF4E와 eIF4G의 결합을 방해하는 저해제가 종양유발 단백질의 세포내 합성을 억제한다는 결과가 있다.Regulation of protein synthesis, especially at the initiation stage, plays a very important role in cell growth, proliferation, differentiation and death. In eukaryotes, several eukaryotic initiation factors (eIFs) exist, which function to properly initiate protein synthesis by ribosome subunits, mRNAs, and initiator tRNAs. For this action, a complex of many factors must combine step by step. Representatively among the factors constituting the complex, eIF4E and eIF4G play an important role. eIF4E and eIF4G are regulated by 4E-BP (eIF4E-binding proteins), which are relatively small proteins. From a recently published study, there is a result that an inhibitor that interferes with the binding of eIF4E and eIF4G instead of the function of 4E-BP inhibits the intracellular synthesis of tumor-inducing proteins.
이처럼, 단백질 합성의 미세한 조절로 종양을 억제하는 연구가 최근 각광받고 있다. 이를 설명할 수 있는 가설로는 “약한 (Weak)” mRNA “강한 (strong)” mRNA 가설이 있다. 종양유발 단백질들은 소위 말하는 “약한” mRNA에 의해 코딩이 되며, 그 합성을 선택적으로 억제하게 되면 정상세포에는 큰 영향을 주지 않으면서 암세포를 사멸시키는 효과를 볼 수 있을 것이라는 가설이며, 이를 뒷받침하는 수많은 연구 결과들이 있다. As such, research on suppressing tumors through fine control of protein synthesis has recently been in the limelight. As a hypothesis that can explain this, there is a “weak” mRNA “strong” mRNA hypothesis. It is hypothesized that tumor-inducing proteins are coded by so-called “weak” mRNAs, and that selective inhibition of their synthesis will have the effect of killing cancer cells without significantly affecting normal cells. There are research results.
단백질 합성의 개시에서 또 하나의 중요한 단계로 eIF2, GTP, 그리고 개시 메티오닌 tRNA (initiator methionine tRNA; Met-tRNAi)로 구성되는 삼성분복합체 (ternary complex)의 형성이 있다. 삼성분복합체는 정상적인 세포 기능을 수행하는데 중요한 역할을 하며, 그 조절에 이상이 있을 경우 여러 가지 질병을 유발하는 것으로 알려져 새로운 치료제 개발의 타겟으로 주목받고 있다.Another important step in the initiation of protein synthesis is the formation of a ternary complex composed of eIF2, GTP, and initiator methionine tRNA (Met-tRNAi). The ternary complex plays an important role in carrying out normal cell functions, and when there is an abnormality in its regulation, it is known to cause various diseases and is drawing attention as a target for the development of new treatments.
세포는 다양한 스트레스 상황에 직면하게 될 때 통합 스트레스 반응 (integrated stress response) 경로를 활성화하여 세포 내 변화에 대응하기 위해 단백질의 합성을 조절한다. 진핵생물에서 통합 스트레스 반응은 진핵생물 번역 개시 인자 (eukaryotic translation initiation factor 2α,eIF2α)의 인산화로 수렴되며, 이는 스트레스를 감지하는 4종의 eIF2α 카이네이즈(HRI, PERK, GCN2, PKR)의 활성화로 인해 매개된다. eIF2α의 인산화가 일어나면 전반적인 단백질 합성은 저해되고, 역설적으로 스트레스에 대처하는 인자인 ATF4 등은 발현이 증가하여 결과적으로 세포의 정상 상태로의 회복을 촉진한다. eIF2α는 세포의 암화 과정에서 과발현 되는 특성을 지니며, 하부 신호전달을 통해 세포 내 단백질의 합성을 조절하므로, eIF2α의 인산화를 암세포 특이적인 대사 조절 표적으로 간주할 수 있다. 최근의 연구로부터 eIF2α의 인산화를 촉진하여 항암 효과를 유도할 수 있음이 보고되었으며, Halperin 연구팀이 개발한 유레아 모핵을 지닌 화합물의 eIF2α 인산화 효능 및 항암 활성이 우수함을 확인하였다. 하지만, 현재까지 임상시험 단계로 진입한 eIF2α 인산화 효능이 있는 저분자 후보물질은 보고된 바가 없다. 따라서 추가 연구의 필요성이 충분하고 사료되며, 이 기전을 이용한 대사항암제를 개발이 진행 중이다.When cells are faced with various stress situations, they activate integrated stress response pathways to regulate protein synthesis to respond to intracellular changes. In eukaryotes, the integrated stress response converges on the phosphorylation of eukaryotic translation initiation factor 2α and eIF2α, which is due to the activation of four stress-sensing eIF2α kinases (HRI, PERK, GCN2, and PKR). mediated When phosphorylation of eIF2α occurs, overall protein synthesis is inhibited, and paradoxically, the expression of ATF4, a factor that copes with stress, and the like increases, thereby promoting the recovery of cells to a normal state. Since eIF2α is overexpressed during cell cancerization and regulates intracellular protein synthesis through downstream signaling, phosphorylation of eIF2α can be regarded as a cancer cell-specific metabolic control target. It has been reported from a recent study that an anticancer effect can be induced by promoting phosphorylation of eIF2α, and it was confirmed that the compound having a urea moiety developed by the Halperin research team has excellent eIF2α phosphorylation efficacy and anticancer activity. However, there has been no report of a small molecule candidate with eIF2α phosphorylation efficacy that has entered the clinical trial stage to date. Therefore, it is believed that the need for additional research is sufficient, and development of metabolic cancer drugs using this mechanism is in progress.
본 발명의 목적은 2-아미노벤조티아졸 유도체 화합물, 이의 약학적으로 허용가능한 염, 이의 용매화물 또는 이의 입체이성질체에서 선택된 화합물을 제공하는 데에 있다.An object of the present invention is to provide a compound selected from 2-aminobenzothiazole derivative compounds, pharmaceutically acceptable salts thereof, solvates thereof, and stereoisomers thereof.
본 발명의 또 다른 목적은 상기 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물을 제공하는 데에 있다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer containing the compound as an active ingredient.
본 발명의 또 다른 목적은 상기 화합물을 유효성분으로 함유하는 대사항암제용 약학조성물을 제공하는 데에 있다.Another object of the present invention is to provide a pharmaceutical composition for anticancer agents containing the compound as an active ingredient.
본 발명의 또 다른 목적은 상기 화합물을 투여하는 단계를 포함하는 암세포 대사 억제방법을 제공하는 데에 있다.Another object of the present invention is to provide a method for inhibiting cancer cell metabolism comprising administering the compound.
본 발명의 또 다른 목적은 상기 화합물을 유효성분으로 함유하는 암 예방 또는 개선용 건강기능식품 조성물을 제공하는 데에 있다.Another object of the present invention is to provide a health functional food composition for preventing or improving cancer containing the compound as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 2-아미노벤조티아졸 유도체 화합물, 이의 약학적으로 허용가능한 염, 이의 용매화물 또는 이의 입체이성질체에서 선택된 화합물을 제공한다.In order to achieve the above object, the present invention provides a compound selected from a 2-aminobenzothiazole derivative compound represented by Formula 1 below, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof.
[화학식 1][Formula 1]
상기 화학식 1에서, In Formula 1,
R1 및 R2는 각각 동일하거나 다를 수 있고, 수소 (H), 할로겐, 트리플루오로메틸 (CF3), 나이트로 (NO2), (C1~C4)알콕시, 트리플루오로메톡시 (OCF3), 시아노 (CN), 나이트로 (NO2), (C1~C4)알킬술포닐 및 아미노술포닐 (SO2NH2)로 이루어진 군에서 선택된다.R 1 and R 2 may each be the same or different, and hydrogen (H), halogen, trifluoromethyl (CF 3 ), nitro (NO 2 ), (C1~C4) alkoxy, trifluoromethoxy (OCF 3 ), cyano (CN), nitro (NO 2 ), (C1~C4) alkylsulfonyl and aminosulfonyl (SO 2 NH 2 ).
또한, 본 발명은 상기 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer containing the compound as an active ingredient.
또한, 본 발명은 상기 화합물을 유효성분으로 함유하는 대사항암제용 약학조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for anticancer agents containing the compound as an active ingredient.
또한, 본 발명은 상기 화합물을 투여하는 단계를 포함하는 암세포 대사 억제방법을 제공한다. In addition, the present invention provides a method for inhibiting cancer cell metabolism comprising administering the compound.
또한, 본 발명은 상기 화합물을 유효성분으로 함유하는 암 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving cancer containing the compound as an active ingredient.
본 발명은 eIF2α 인산화 효능을 통한 항암 활성을 나타내는 2-아미노벤조티아졸 유도체 화합물, 이의 약학적으로 허용가능한 염, 이의 용매화물 또는 이의 입체이성질체에서 선택된 화합물에 관한 것으로, 합성된 신규 유도체는 eIF2α 인산화 효과 및 인 비트로 (in vitro)에서 암세포 증식 저해 활성을 보여, 대사항암제로서 백혈병, 그 이외에도 유방암, 뇌종양, 육종 등의 희귀암에 대한 예방 및 개선을 위한 제약 및 건강기능식품 조성물로 활용 가능하다.The present invention relates to a compound selected from the group consisting of a 2-aminobenzothiazole derivative compound, a pharmaceutically acceptable salt thereof, a solvate thereof, and a stereoisomer thereof, which exhibit anticancer activity through phosphorylation of eIF2α. It can be used as a pharmaceutical and health functional food composition for the prevention and improvement of rare cancers such as breast cancer, brain tumor, and sarcoma, as well as leukemia as a metabolizing cancer agent, as it shows cancer cell growth inhibitory effect and in vitro.
도 1은 N-(4-아릴옥시사이클로헥실)벤조티아졸-2-아민 [N-(4-aryloxycyclohexyl)benzothiazole-2-amine] 유도체 설계전략을 나타낸다.
도 2는 N-(4-아릴옥시사이클로헥실)벤조티아졸-2-아민 [N-(4-aryloxycyclohexyl)benzothiazole-2-amine] 유도체의 합성예를 나타낸다.Figure 1 shows the N- (4-aryloxycyclohexyl)benzothiazol-2-amine [ N- (4-aryloxycyclohexyl)benzothiazole-2-amine] derivative design strategy.
Figure 2 shows a synthesis example of N- (4-aryloxycyclohexyl)benzothiazole-2-amine [ N- (4-aryloxycyclohexyl)benzothiazole-2-amine] derivative.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
단백질 합성의 개시에서 중요한 단계로 eIF2, GTP, 그리고 Met-tRNAi로 구성되는 복합체의 형성이 있다. 이 복합체는 정상적인 세포 기능을 수행하는데 중요한 역할을 하며, 그 조절에 이상이 있을 경우 여러 가지 질병을 유발하는 것으로 알려져 새로운 치료제 개발의 타겟으로 주목받고 있는데, 본 발명자들은 다양한 치환기를 지닌 2-아미노벤조티아졸 유도체 화합물을 합성하였으며, 이렇게 합성된 신규 유도체는 eIF2α 인산화 효과 및 인 비트로(in vitro)에서 암세포 증식 저해 활성을 보이는 것을 확인하고, 본 발명을 완성하였다.An important step in the initiation of protein synthesis is the formation of a complex composed of eIF2, GTP, and Met-tRNAi. This complex plays an important role in carrying out normal cellular functions, and is known to cause various diseases when there is an abnormality in its regulation, attracting attention as a target for the development of new therapeutic agents. A thiazole derivative compound was synthesized, and it was confirmed that the novel derivative thus synthesized showed an eIF2α phosphorylation effect and cancer cell proliferation inhibitory activity in vitro, thereby completing the present invention.
상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 2-아미노벤조티아졸 유도체 화합물, 이의 약학적으로 허용가능한 염, 이의 용매화물 또는 이의 입체이성질체에서 선택된 화합물을 제공한다.In order to achieve the above object, the present invention provides a compound selected from a 2-aminobenzothiazole derivative compound represented by Formula 1 below, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof.
[화학식 1] [Formula 1]
상기 화학식 1에서, In Formula 1,
R1 및 R2는 각각 동일하거나 다를 수 있고, 수소 (H), 할로겐, 트리플루오로메틸 (CF3), 나이트로 (NO2), (C1~C4)알콕시, 트리플루오로메톡시 (OCF3), 시아노 (CN), 나이트로 (NO2), (C1~C4)알킬술포닐 및 아미노술포닐 (SO2NH2)로 이루어진 군에서 선택될 수 있다.R 1 and R 2 may each be the same or different, and hydrogen (H), halogen, trifluoromethyl (CF 3 ), nitro (NO 2 ), (C1~C4) alkoxy, trifluoromethoxy (OCF 3 ), cyano (CN), nitro (NO 2 ), (C1~C4) alkylsulfonyl, and aminosulfonyl (SO 2 NH 2 ).
바람직하게는, 상기 2-아미노벤조티아졸 유도체 화합물은 화학식 1에서 R1은 수소 (H), 플루오린 (F), 염소 (Cl), 트리플루오로메틸 (CF3), 나이트로 (NO2) 및 (C1~C2)알콕시로 이루어진 군에서 선택되며, R2는 염소 (Cl), 트리플루오로메틸 (CF3), 트리플루오로메톡시 (OCF3), 시아노 (CN), 나이트로 (NO2), (C1~C2)알킬술포닐 및 아미노술포닐 (SO2NH2)로 이루어진 군에서 선택될 수 있다.Preferably, in the 2-aminobenzothiazole derivative compound, R 1 in
보다 바람직하게는, 상기 2-아미노벤조티아졸 유도체 화합물은 화학식 1에서 R1은 수소 (H), 플루오린 (F), 염소 (Cl), 트리플루오로메틸 (CF3), 나이트로 (NO2) 및 메톡시(OMe)로 이루어진 군에서 선택되며, R2는 염소 (Cl), 트리플루오로메틸 (CF3), 트리플루오로메톡시 (OCF3), 시아노 (CN), 나이트로 (NO2), 메틸술포닐 (SO2Me) 및 아미노술포닐 (SO2NH2)로 이루어진 군에서 선택될 수 있다.More preferably, in the 2-aminobenzothiazole derivative compound, R 1 in
일 실시예로는, 상기 2-아미노벤조티아졸 유도체 화합물은 N-((1,4-트랜스)-4-(4-클로로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-Chlorophenoxy)cyclohexyl)benzo[d]thiazol-2-amine], N-((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-(Trifluoromethyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], N-((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-(Trifluoromethoxy)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-(벤조[d]티아졸-2-일아미노)사이클로헥실)옥시)벤조나이트릴 [4-(((1,4-trans)-4-(Benzo[d]thiazol-2-ylamino)cyclohexyl)oxy)benzonitrile], N-((1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-Nitrophenoxy)cyclohexyl)benzo[d]thiazol-2-amine], N-((1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-(벤조[d]티아졸-2-일아미노)사이클로헥실)옥시)벤젠술폰아마이드 [4-(((1,4-trans)-4-(Benzo[d]thiazol-2-ylamino)cyclohexyl)oxy)benzenesulfonamide], N-((1,4-트랜스)-4-(4-클로로페녹시)사이클로헥실)-6-플루오로벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-Chlorophenoxy)cyclohexyl)-6-fluorobenzo[d]thiazol-2-amine], 6-플루오로-N-((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Fluoro-N-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 6-플루오로-N-((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Fluoro-N-((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-플루오로벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤조나이트릴 [4-(((1,4-trans)-4-((6-Fluorobenzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile], 6-플루오로-N-((1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Fluoro-N-((1,4-trans)-4-(4-nitrophenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 6-플루오로-N-((1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Fluoro-N-((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-플루오로벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤젠술폰아마이드 [4-(((1,4-trans)-4-((6-Fluorobenzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide], 6-클로로-N-((1,4-트랜스)-4-(4-클로로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Chloro-N-((1,4-trans)-4-(4-chlorophenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 6-클로로-N-((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Chloro-N-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 6-클로로-N-((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Chloro-N-((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-클로로벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤조나이트릴 [4-(((1,4-trans)-4-((6-Chlorobenzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile], 6-클로로-N-((1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Chloro-N-((1,4-trans)-4-(4-nitrophenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 6-클로로-N-((1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Chloro-N-((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-클로로벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤젠술폰아마이드 [4-(((1,4-trans)-4-((6-Chlorobenzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide], N-((1,4-트랜스)-4-(4-클로로페녹시)사이클로헥실)-6-(트리플루오로메틸)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-Chlorophenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[d]thiazol-2-amine], 6-(트리플루오로메틸)-N-((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-(Trifluoromethyl)-N-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], N-((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)-6-(트리플루오로메틸)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-(Trifluoromethoxy)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-(트리플루오로메틸)벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤조나이트릴 [4-(((1,4-trans)-4-((6-(Trifluoromethyl)benzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile], N-((1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥실)-6-(트리플루오로메틸)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-Nitrophenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[d]thiazol-2-amine], N-((1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥실)-6-(트리플루오로메틸)벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-(트리플루오로메틸)벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤젠술폰아마이드 [4-(((1,4-trans)-4-((6-(Trifluoromethyl)benzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide], N-((1,4-트랜스)-4-(4-클로로페녹시)사이클로헥실)-6-나이트로벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-Chlorophenoxy)cyclohexyl)-6-nitrobenzo[d]thiazol-2-amine], 6-나이트로-N-((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Nitro-N-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 6-나이트로-N-((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Nitro-N-((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-나이트로벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤조나이트릴 [4-(((1,4-trans)-4-((6-Nitrobenzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile], 6-나이트로-N-((1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Nitro-N-((1,4-trans)-4-(4-nitrophenoxy)cyclohexyl)benzo[d]thiazol-2-amine], N-((1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥실)-6-나이트로벤조[d]티아졸-2-아민 [N-((1,4-trans)-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)-6-nitrobenzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-나이트로벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤젠술폰아마이드 [4-(((1,4-trans)-4-((6-Nitrobenzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide], 6-메톡시-N-((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Methoxy-N-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine], 4-(((1,4-트랜스)-4-((6-메톡시벤조[d]티아졸-2-일)아미노)사이클로헥실)옥시)벤조나이트릴 [4-(((1,4-trans)-4-((6-Methoxybenzo[d]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile], 6-메톡시-N-((1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Methoxy-N-((1,4-trans)-4-(4-nitrophenoxy)cyclohexyl)benzo[d]thiazol-2-amine] 및 6-메톡시-N-((1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [6-Methoxy-N-((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[d]thiazol-2-amine]으로 이루어진 군에서 선택될 수 있으나, 이에 한정되는 것은 아니다.In one embodiment, the 2-aminobenzothiazole derivative compound is N -((1,4-trans)-4-(4-chlorophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-(4-Chlorophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], N -((1,4-trans)-4-(4-(trifluoro) Romethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-(4-(Trifluoromethyl)phenoxy)cyclohexyl)benzo[d]thiazol-2 -amine], N -((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [ N -((1,4 - trans )-4-(4-(Trifluoromethoxy)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-(benzo[ d ]thiazol-2 -ylamino)cyclohexyl)oxy)benzonitrile [4-(((1,4- trans )-4-(Benzo[ d ]thiazol-2-ylamino)cyclohexyl)oxy)benzonitrile], N -((1 ,4-trans)-4-(4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-(4-Nitrophenoxy)cyclohexyl) benzo[ d ]thiazol-2-amine], N -((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-(benzo[ d ] Thiazol-2-ylamino) cyclohexyl) oxy) benzenesulfonamide [4-(((1,4- trans ) -4-(Benzo [ d ] thiazol-2-ylamino) cyclohexyl) oxy) benzenesulfonamide] , N -((1,4-trans S) -4- (4-chlorophenoxy) cyclohexyl) -6-fluorobenzo [ d ] thiazol-2-amine [ N -((1,4- trans )-4-(4-Chlorophenoxy) cyclohexyl )-6-fluorobenzo[ d ]thiazol-2-amine], 6-fluoro- N -((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Fluoro- N -((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 6-fluoro Rho- N -((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Fluoro- N -((1 ,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-((6-fluorobenzo [ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile [4-(((1,4- trans )-4-((6-Fluorobenzo[ d ]thiazol-2-yl)amino )cyclohexyl)oxy)benzonitrile], 6-fluoro- N -((1,4-trans)-4-(4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6- Fluoro- N -((1,4- trans )-4-(4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 6-fluoro- N -((1,4-trans)-4 -(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Fluoro- N -((1,4- trans )-4-(4-(methylsulfonyl)phenoxy )cyclohexyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-((6-fluorobenzo[ d ]thiazol-2-yl)amino)cyclohexyl) Oxy) benzenesulfonamide [4-(((1,4- trans )-4-((6-Flu orobenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide], 6-chloro- N -((1,4-trans)-4-(4-chlorophenoxy)cyclohexyl)benzo[ d ] Thiazol-2-amine [6-Chloro- N -((1,4- trans )-4-(4-chlorophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 6-chloro- N -(( 1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Chloro- N -((1,4- trans )- 4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 6-chloro- N -((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy cy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Chloro- N -((1,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ d ]thiazol-2 -amine], 4-(((1,4-trans)-4-((6-chlorobenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile [4-((( 1,4- trans )-4-((6-Chlorobenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile], 6-chloro- N -((1,4-trans)-4-( 4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Chloro- N -((1,4- trans )-4-(4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazol -2-amine], 6-chloro- N -((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6- Chloro- N -((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4- ((6-chlorobenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide [4-(((1,4- trans )-4-((6-Chlorobenzo[ d ]thiazol -2-yl)amino)cyclohexyl)oxy)benzenesulfonamide], N -((1,4-trans)-4-(4-chlorophenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ d ] Thiazol-2-amine [ N -((1,4- trans )-4-(4-Chlorophenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ d ]thiazol-2-amine], 6-(trifluoro Methyl)- N -((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-(Trifluoromethyl)- N - ((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], N -((1,4-trans)-4-(4-(tri) Fluoromethoxy)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-(4-(Trifluoromethoxy)phenoxy )cyclohexyl)-6-(trifluoromethyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-((6-(trifluoromethyl)benzo[ d ]thiazole -2-yl)amino)cyclohexyl)oxy)benzonitrile [4-(((1,4- trans )-4-((6-(Trifluoromethyl)benzo[ d ]thiazol-2-yl)amino)cyclohexyl )oxy)benzonitrile], N -((1,4-trans)-4-(4-nitrophenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-(4-Nitrophenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ d ]thiazol-2-amine], N -((1,4-trans) -4-(4-(methylsulfonyl)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4- (4-(Methylsulfonyl)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-((6-(trifluoromethyl) )benzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide [4-(((1,4- trans )-4-((6-(Trifluoromethyl)benzo[ d ]thiazol- 2-yl)amino)cyclohexyl)oxy)benzenesulfonamide], N -((1,4-trans)-4-(4-chlorophenoxy)cyclohexyl)-6-nitrobenzo[ d ]thiazole-2- Amine [ N -((1,4- trans )-4-(4-Chlorophenoxy)cyclohexyl)-6-nitrobenzo[ d ]thiazol-2-amine], 6-nitro- N -((1,4-trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Nitro- N -((1,4- trans )-4-(4- (trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 6-nitro- N -((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl ) Benzo[ d ]thiazol-2-amine [6-Nitro- N -((1,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-((6-nitrobenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile [4-(((1,4 - trans )-4-((6-Nitrobenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile], 6-nitro- N -((1,4-trans)-4-(4- nitrophenoxy)cyclohexyl)benzo[ d ] Thiazol-2-amine [6-Nitro- N -((1,4- trans )-4-(4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], N -((1,4- trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)-6-nitrobenzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-(4 -(Methylsulfonyl)phenoxy)cyclohexyl)-6-nitrobenzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-((6-nitrobenzo[ d ]thiazol-2 -yl)amino)cyclohexyl)oxy)benzenesulfonamide [4-(((1,4- trans )-4-((6-Nitrobenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide] , 6-methoxy- N -((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Methoxy- N -((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine], 4-(((1,4-trans)-4-((6 -Methoxybenzo[ d ]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile [4-(((1,4- trans )-4-((6-Methoxybenzo[ d ]thiazol-2 -yl)amino)cyclohexyl)oxy)benzonitrile], 6-methoxy- N -((1,4-trans)-4-(4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazole-2- Amine [6-Methoxy- N -((1,4- trans )-4-(4-nitrophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine] and 6-methoxy- N -((1,4- trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [6-Methoxy- N -((1,4- trans )-4-(4- (methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ] thiazol-2-amine], but is not limited thereto.
또한, 본 발명은 상기 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer containing the compound as an active ingredient.
바람직하게는, 본 발명에 따른 화합물은 진핵생물 번역 개시 인자 2α(eukaryotic translation initiation factor 2α, eIF2α)의 인산화를 촉진할 수 있다.Preferably, the compound according to the present invention can promote phosphorylation of eukaryotic translation initiation factor 2α (eIF2α).
바람직하게는, 상기 암은 혈액암, 유방암, 육종암 또는 뇌암일 수 있으나, 이에 한정되는 것은 아니다.Preferably, the cancer may be blood cancer, breast cancer, sarcoma cancer or brain cancer, but is not limited thereto.
또한, 본 발명은 상기 화합물을 유효성분으로 함유하는 대사항암제용 약학조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for anticancer agents containing the compound as an active ingredient.
또한, 본 발명은 상기 화합물을 투여하는 단계를 포함하는 암세포 대사 억제방법을 제공한다.In addition, the present invention provides a method for inhibiting cancer cell metabolism comprising administering the compound.
상기 화합물은 진핵생물 번역 개시 인자 2α(eukaryotic translation initiation factor 2α; eIF2α)의 인산화를 촉진하여 암세포의 대사를 차단하여 사멸시킬 수 있다.The compound can promote phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) to block metabolism of cancer cells and kill them.
상기 대사항암제는 화학항암제, 표적항암제 및 면역항암제의 뒤를 잇는 4세대 항암제로 불리며, 정상세포에 비해 활발하게 세포 분열을 일으키는 암세포 대사 활동을 차단하는 방식으로, 기존 항암 치료제와 달리 암세포 대사과정을 차단하여 암세포만 골라 죽이는 항암제이며, 특히 암세포 대사량을 50 % 이상 낮추고, 암세포 성장을 억제하는 과정에서 정상세포에 대한 피해가 거의 없다는 것이 특징이다. The metabolic anti-cancer agent is called the 4th generation anti-cancer agent following chemical anti-cancer agent, targeted anti-cancer agent, and immuno-anticancer agent, and blocks the metabolic activity of cancer cells that actively cause cell division compared to normal cells. It is an anticancer agent that selects and kills only cancer cells, and in particular, it lowers the metabolism of cancer cells by more than 50% and has little damage to normal cells in the process of suppressing cancer cell growth.
본 발명에서, 상기 약학적으로 허용가능한 염은 나트륨염, 칼륨염, 칼슘염, 리튬염, 마그네슘염, 세슘염, 아미늄(aminium)염, 암모늄염, 트리에칠아미늄염 및 피리디늄염으로 이루어진 군에서 선택된 하나 이상의 염기성 염일 수 있으나, 이에 제한되는 것은 아님을 명시한다.In the present invention, the pharmaceutically acceptable salt is composed of sodium salt, potassium salt, calcium salt, lithium salt, magnesium salt, cesium salt, aminium salt, ammonium salt, triethylaminium salt and pyridinium salt. It may be one or more basic salts selected from the group, but is not limited thereto.
또한, 상기 약학적으로 허용가능한 염은 염산, 브롬산, 황산, 아황산, 인산, 구연산, 초산, 말레산, 퓨마르산, 글루코산, 메탄설폰산, 벤젠설폰산, 캠퍼설폰산, 옥살산, 말론산, 글루타릭산, 아세트산, 글리콘산, 석신산, 타타르산, 4-톨루엔설폰산, 갈락투론산, 엠본산, 글루탐산, 시트르산 및 아스파르탄산으로 이루어진 군에서 선택된 하나 이상의 산성 염일 수 있으나, 이에 제한되는 것은 아님을 명시한다.In addition, the pharmaceutically acceptable salts are hydrochloric acid, hydrobromic acid, sulfuric acid, sulfurous acid, phosphoric acid, citric acid, acetic acid, maleic acid, fumaric acid, glucoic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, oxalic acid, malonic acid , It may be one or more acid salts selected from the group consisting of glutaric acid, acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid and aspartic acid, but Note that it is not limited.
본 발명의 약학 조성물은 투여를 위하여, 상기 기재한 성분 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.For administration, the pharmaceutical composition of the present invention may include pharmaceutically acceptable carriers, excipients or diluents in addition to the components described above. The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용할 수 있다. 상세하게는 제형화할 경우 통상 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제로는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하나, 이에 한정되는 것은 아니다. 이러한 고형 제제는 상기 유효성분 외에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트, 수크로오스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 첨가하여 조제될 수 있다. 비경구 투여를 위한 제제는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제 및 과제를 포함한다. 비수성 용제 및 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로솔, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories or sterile injection solutions according to conventional methods. . Specifically, when formulated, it may be prepared using diluents or excipients such as commonly used fillers, weighting agents, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation may be prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc., in addition to the active ingredient. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. It may be prepared by adding various excipients, for example, wetting agents, sweeteners, aromatics, and preservatives, in addition to liquids and liquid paraffin for oral use. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations and tablets. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for suppositories, Witepsol, Macrosol, Tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
본 발명의 약학 조성물은 경구형 또는 비경구형 제제로 제조할 수 있으며, 경구, 정맥, 뇌실내, 진피내, 근육내, 복막내, 비강 또는 경막외(eidural) 경로로 투여할 수 있으나, 이에 제한되는 것은 아님을 명시한다.The pharmaceutical composition of the present invention may be prepared as an oral or parenteral formulation, and may be administered by oral, intravenous, intraventricular, intradermal, intramuscular, intraperitoneal, nasal or epidural route, but is limited thereto. indicate that it is not
본 발명의 약학 조성물의 적합한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있는 바, 상기 조성물의 일일 투여량은 바람직하게는 0.01 mg/kg 내지 100 mg/kg이며, 필요에 따라 일일 1회 내지 수회로 나누어 투여할 수 있다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the type of drug, and time, but can be appropriately selected by a person skilled in the art, and the daily dosage of the composition is preferably 0.01 It is mg/kg to 100 mg/kg, and it can be divided and administered once a day to several times as needed.
또한, 본 발명은 상기 화합물을 유효성분으로 함유하는 암 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving cancer containing the compound as an active ingredient.
상기 건강기능식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스, 합성 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강기능식품 조성물은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.The health functional food composition includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts , organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, synthetic fruit juice and vegetable beverages. These components may be used independently or in combination. In addition, the health functional food composition is any one form of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin complex can be
또한, 상기 건강기능식품 조성물은 식품첨가물을 추가로 포함할 수 있으며, 식품첨가물로서의 적합 여부는 다른 규정이 없는 한 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반 시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health functional food composition may further contain food additives, and the suitability as a food additive is determined according to the general rules of the Food Additive Code and general test methods approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the relevant standards and standards.
상기 식품첨가물공전에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류 첨가 알칼리제, 보존료제제, 타르색소 제제 등의 혼합 제제류 등을 들 수 있다.Items listed in the Food Additive Code, for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as persimmon pigment, licorice extract, crystalline cellulose, goreng pigment, guar gum, and L-glutamic acid and mixed formulations such as sodium formulations, noodle-added alkali formulations, preservative formulations, and tar color formulations.
이때, 건강기능식품 조성물을 제조하는 과정에서 식품에 첨가되는 본 발명에 따른 조성물은 필요에 따라 그 함량을 적절히 가감할 수 있다.At this time, the content of the composition according to the present invention added to food in the process of preparing the health functional food composition can be appropriately increased or decreased as needed.
이하에서는 실시예 및 실험예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예 및 실험예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예 및 실험예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples and experimental examples. These Examples and Experimental Examples are only for explaining the present invention in more detail, and it is common knowledge in the art that the scope of the present invention is not limited by these Examples and Experimental Examples according to the gist of the present invention. It will be self-evident in the chair.
[합성예][Synthesis Example]
1. N-((1,4-트랜스)-4-(4-클로로페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [ N -((1,4- trans )-4-(4-Chlorophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine] (화합물 1) 1. N -((1,4-trans)-4-(4-chlorophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine [ N -((1,4- trans )-4-( 4-Chlorophenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine] (Compound 1)
2-클로로벤조티아졸 (2-chlorobenzothiazole; 76.7 μL, 0.59 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-클로로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-chlorophenoxy)cyclohexan-1-amine; 66.6 mg, 0.30 mmol) 및 탄산칼륨 (K2CO3; 81.4 mg, 0.59 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산:디클로로메탄=1:20:10)에 의해 정제하여 25.2 mg (12 %)의 화합물 1을 담황색 고체로서 수득하였다.(1,4-trans)-4-(4-chlorophenoxy)cyclohexan-1-amine ( (1,4-trans)-4-(4-chlorophenoxy)cyclohexan-1-amine; 66.6 mg, 0.30 mmol) and potassium carbonate (K 2 CO 3 ; 81.4 mg, 0.59 mmol) at ambient temperature. Added. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane: dichloromethane=1:20:10) to give 25.2 mg (12%) of
1H NMR (CDCl3, 500 MHz) δ 7.59 (d, 1H, J = 7.8 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.23 (d, 2H, J = 8.9 Hz), 7.09 (t, 1H, J = 7.6 Hz), 6.83 (d, 2H, J = 8.9 Hz), 5.48 (s, 1H), 4.18 (m, 1H), 3.71 (m, 1H), 2.30 (m, 2H), 2.15 (m, 2H), 1.65 (m, 2H), 1.43 (m, 2H); 13C NMR (CDCl3 , 125 MHz) δ 166.6, 156.3, 152.5, 130.5, 129.5, 126.1, 125.9, 121.7, 120.9, 119.0, 117.5, 75.2, 53.5, 30.4, 29.9. 1H NMR (CDCl 3 , 500 MHz) δ 7.59 (d, 1H, J = 7.8 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.23 (d , 2H, J = 8.9 Hz), 7.09 (t, 1H, J = 7.6 Hz), 6.83 (d, 2H, J = 8.9 Hz), 5.48 (s, 1H), 4.18 (m, 1H), 3.71 (m , 1H), 2.30 (m, 2H), 2.15 (m, 2H), 1.65 (m, 2H), 1.43 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.6, 156.3, 152.5, 130.5, 129.5, 126.1, 125.9, 121.7, 120.9, 119.0, 117.5, 75.2, 53.5, 30.4, 29.9.
2. N-((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[d]티아졸-2-아민 [ N -((1,4-trans)-4-(4-(Trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine] (화합물 2) 2. N -((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ] thiazol-2-amine [ N -((1,4-trans )-4-(4-(Trifluoromethyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine] (Compound 2)
2- 클로로벤조티아졸 (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol )이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 76.4 mg, 0.30 mmol) 및 탄산칼륨 (K2CO3; 81.4mg, 0.59 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:4)에 의해 정제하여 60.8 mg (53 %)의 화합물 2를 아이보리색 고체로서 수득하였다.( 1,4 -trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexane in DMF (1.5 mL) containing 2- chlorobenzothiazole (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol ). -1-amine ((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 76.4 mg, 0.30 mmol) and potassium carbonate (K 2 CO 3 ; 81.4 mg, 0.59 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:4) to give 60.8 mg (53%) of
1H NMR (CDCl3, 500 MHz) δ 7.59 (d, 1H, J = 7.9 Hz), 7.54 (d, 1H, J = 7.4 Hz), 7.53 (d, 2H, J = 8.5 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.10 (t, 1H, J = 7.6 Hz), 6.95 (d, 2H, J = 8.6 Hz), 5.46 (s, 1H), 4.31 (m, 1H), 3.74 (m, 1H), 2.32 (m, 2H), 2.18 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.6, 160.2, 152.4, 130.4, 127.8, 127.1, 127.1, 127.1, 127.0, 126.2, 125.6, 123.5, 123.4, 123.1, 122.8, 122.6, 121.8, 121.3, 121.0, 119.0, 115.7, 74.8, 53.4, 30.4, 29.7. 1H NMR (CDCl 3 , 500 MHz) δ 7.59 (d, 1H, J = 7.9 Hz), 7.54 (d, 1H, J = 7.4 Hz), 7.53 (d, 2H, J = 8.5 Hz), 7.30 (t , 1H, J = 7.7 Hz), 7.10 (t, 1H, J = 7.6 Hz), 6.95 (d, 2H, J = 8.6 Hz), 5.46 (s, 1H), 4.31 (m, 1H), 3.74 (m , 1H), 2.32 (m, 2H), 2.18 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 166.6, 160.2, 152.4, 127.8, 127.1, 127.1, 127.1, 127.0, 126.2, 125.6, 123.5, 123.4, 123.1, 122.8, 122.6, 121.8, 121.3, 121.0, 119.0, 119.0 , 115.7, 74.8, 53.4, 30.4, 29.7.
3. 3. NN -((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 []Thiazol-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-(Trifluoromethoxy)phenoxy)cyclohexyl)benzo[)-4-(4-(Trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 3)]thiazol-2-amine] (Compound 3)
2- 클로로벤조티아졸 (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol )이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 81.0 mg, 0.30 mmol) 및 탄산칼륨 (K2CO3; 81.4 mg, 0.59 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 13.2 mg (11 %)의 화합물 3을 흰색 고체로서 수득하였다.( 1,4 - trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexane was added to DMF (1.5 mL) containing 2- chlorobenzothiazole (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol ). -1-amine ((1,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 81.0 mg, 0.30 mmol) and potassium carbonate (K 2 CO 3 ; 81.4 mg, 0.59 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 13.2 mg (11%) of compound 3 as a white solid.
1H NMR (CDCl3, 500 MHz) δ 7.59 (d, 1H, J = 7.9 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.13 (d, 2H, J = 8.8 Hz), 7.09 (t, 1H, J = 7.6 Hz), 6.88 (d, 2H, J = 9.1 Hz), 5.34 (s, 1H), 4.21 (m, 1H), 3.73 (m, 1H), 2.31 (m, 2H), 2.17 (m, 2H), 1.67 (m, 2H), 1.44 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.5, 156.2, 152.5, 142.9, 142.9, 130.5, 126.1, 123.8, 122.6, 121.8, 121.7, 121.0, 119.7, 119.0, 117.6, 116.9, 75.3, 53.4, 30.4, 29.9. 1H NMR (CDCl 3 , 500 MHz) δ 7.59 (d, 1H, J = 7.9 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.13 (d , 2H, J = 8.8 Hz), 7.09 (t, 1H, J = 7.6 Hz), 6.88 (d, 2H, J = 9.1 Hz), 5.34 (s, 1H), 4.21 (m, 1H), 3.73 (m , 1H), 2.31 (m, 2H), 2.17 (m, 2H), 1.67 (m, 2H), 1.44 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 166.5, 156.2, 152.5, 142.9, 130.5, 126.1, 123.8, 122.6, 121.8, 121.7, 121.0, 119.7, 119.0, 117.6, 116.9, 75.3, 53.4, 30.4, 29.9 .
4. 4-(((1,4-트랜스)-4-(4. 4-(((1,4-trans)-4-( 벤조[benzo[ dd ]티아졸]thiazole -2--2- 일아미노ylamino )) 사이클로헥실lcyclohexyl )) 옥시oxy )) 벤조나이트릴benzonitrile [4-(((1,4- [4-(((1,4- transtrans )-4-()-4-( Benzo[Benzo[ dd ]thiazol]thiazol -2-ylamino)cyclohexyl)oxy)benzonitrile ] (화합물 4)-2-ylamino)cyclohexyl)oxy)benzonitrile] (Compound 4)
2- 클로로벤조티아졸 (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol )이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤조나이트릴 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzonitrile; 63.8 mg, 0.30 mmol) 및 탄산칼륨 (K2CO3; 81.4 mg, 0.59 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 66.7 mg (65 %)의 화합물 4를 아이보리색 고체로서 수득하였다. 4 - ((( 1,4 - trans ) -4 - aminocyclohexyl ) oxy)benzonitrile ( 4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzonitrile; 63.8 mg, 0.30 mmol) and potassium carbonate (K 2 CO 3 ; 81.4 mg, 0.59 mmol) were added at ambient temperature. did. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 66.7 mg (65%) of compound 4 as an ivory solid.
1H NMR (CDCl3, 500 MHz) δ 7.59 (m, 1H), 7.57 (d, 2H, J = 8.8 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.09 (t, 1H, J = 7.6 Hz), 6.93 (d, 2H, J = 8.8 Hz), 5.46 (s, 1H), 4.32 (m, 1H), 3.75 (m, 1H), 2.32 (m, 2H), 2.16 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.4, 161.1, 152.4, 134.2, 130.5, 126.1, 121.8, 120.9, 119.4, 119.0, 116.2, 103.9, 75.0, 53.2, 30.3, 29.7. 1H NMR (CDCl 3 , 500 MHz) δ 7.59 (m, 1H), 7.57 (d, 2H, J = 8.8 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.09 (t, 1H, J = 7.6 Hz), 6.93 (d, 2H, J = 8.8 Hz), 5.46 (s, 1H), 4.32 (m, 1H), 3.75 (m, 1H), 2.32 (m, 2H), 2.16 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.4, 161.1, 152.4, 134.2, 130.5, 126.1, 121.8, 120.9, 119.4, 119.0, 116.2, 103.9, 75.0, 53.2, 30.7, 29.7.
5. 5. NN -- (( (1,4-트랜스)-4-(4-(1,4-trans)-4-(4- 나이트로페녹시nitrophenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2--2- 아민amine [ [ NN -((1,4--((1,4- transtrans )-4-(4-Nitrophenoxy)cyclohexyl)benzo[)-4-(4-Nitrophenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 5)]thiazol-2-amine] (Compound 5)
2- 클로로벤조티아졸 (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol )이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-nitrophenoxy)cyclohexan-1-amine; 69.7 mg, 0.30 mmol) 및 탄산칼륨 (K2CO3; 81.4 mg, 0.59 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:1)에 의해 정제하여 32.5 mg (30 %)의 화합물 5를 노란색 고체로서 수득하였다.( 1,4 -trans)-4-(4-nitrophenoxy)cyclohexan-1-amine in DMF (1.5 mL) containing 2- chlorobenzothiazole (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol ) ((1,4- trans )-4-(4-nitrophenoxy)cyclohexan-1-amine; 69.7 mg, 0.30 mmol) and potassium carbonate (K 2 CO 3 ; 81.4 mg, 0.59 mmol) at ambient temperature. added in After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:1) to give 32.5 mg (30%) of
1H NMR (CDCl3, 500 MHz) δ 8.19 (d, 2H, J = 9.1 Hz), 7.59 (d, 1H, J = 7.8 Hz), 7.54 (d, 1H, J = 8.0 Hz), 7.30 (t, 1H, J = 7.7 Hz), 7.10 (t, 1H, J = 7.6 Hz), 6.93 (d, 2H, J = 9.2 Hz), 5.51 (s, 1H), 4.36 (m, 1H), 3.77 (m, 1H), 2.33 (m, 1H), 2.33 (m, 2H), 2.19 (m, 2H), 1.71 (m, 2H), 1.48 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.4, 163.0, 152.4, 141.4, 130.5, 126.1, 126.1, 121.8, 120.9, 119.0, 115.4, 75.4, 53.2, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 8.19 (d, 2H, J = 9.1 Hz), 7.59 (d, 1H, J = 7.8 Hz), 7.54 (d, 1H, J = 8.0 Hz), 7.30 (t , 1H, J = 7.7 Hz), 7.10 (t, 1H, J = 7.6 Hz), 6.93 (d, 2H, J = 9.2 Hz), 5.51 (s, 1H), 4.36 (m, 1H), 3.77 (m , 1H), 2.33 (m, 1H), 2.33 (m, 2H), 2.19 (m, 2H), 1.71 (m, 2H), 1.48 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.4, 163.0, 152.4, 141.4, 130.5, 126.1, 126.1, 121.8, 120.9, 119.0, 115.4, 75.4, 53.2, 30.3, 29.7.
6. 6. NN -- (( (1,4-트랜스)-4-(4-((1,4-trans)-4-(4-( 메틸술포닐methylsulfonyl )) 페녹시phenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)benzo[)-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 6)]thiazol-2-amine] (Compound 6)
2- 클로로벤조티아졸 (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol )이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 87.4 mg, 0.30 mmol) 및 탄산칼륨 (K2CO3; 81.4 mg, 0.59 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=2:1)에 의해 정제하여 47.0 mg (40 %)의 화합물 6을 밝은 노란색 고체로서 수득하였다. ( 1,4 - trans ) -4- ( 4- (methylsulfonyl)phenoxy ) cyclohexane- 1-amine ((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 87.4 mg, 0.30 mmol) and potassium carbonate (K 2 CO 3 ; 81.4 mg, 0.59 mmol) Added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=2:1) to give 47.0 mg (40%) of
1H NMR (CDCl3, 500 MHz) δ 7.85 (d, 2H, J = 8.8 Hz), 7.58 (d, 1H, J = 7.8 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (m, 1H), 7.09 (m, 1H), 7.00 (d, 2H, J = 8.9 Hz), 5.33 (s, 1H), 4.36 (m, 1H), 3.77 (m, 1H), 3.03 (s, 3H), 2.32 (m, 2H), 2.18 (m, 2H), 1.70 (m, 2H), 1.48 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.3, 162.0, 152.5, 132.2, 130.5, 129.8, 126.1, 121.8, 120.9, 119.1, 116.0, 75.1, 53.1, 45.0, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 7.85 (d, 2H, J = 8.8 Hz), 7.58 (d, 1H, J = 7.8 Hz), 7.54 (d, 1H, J = 8.1 Hz), 7.30 (m , 1H), 7.09 (m, 1H), 7.00 (d, 2H, J = 8.9 Hz), 5.33 (s, 1H), 4.36 (m, 1H), 3.77 (m, 1H), 3.03 (s, 3H) , 2.32 (m, 2H), 2.18 (m, 2H), 1.70 (m, 2H), 1.48 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.3, 162.0, 152.5, 132.2, 130.5, 129.8, 126.1, 121.8, 120.9, 119.1, 116.0, 75.1, 53.1, 45.0, 30.7.3, 29.7.
7. 4-(((1,4-트랜스)-4-(7. 4-(((1,4-trans)-4-( 벤조[benzo[ dd ]티아졸]thiazole -2--2- 일아미노ylamino )) 사이클로헥실cyclohexyl )) 옥시oxy )) 벤젠술폰아마이드Benzenesulfonamide [4-(((1,4- [4-(((1,4- transtrans )-4-()-4-( Benzo[Benzo[ dd ]thiazol]thiazol -2-ylamino)cyclohexyl)oxy)benzenesulfonamide] (화합물 7)-2-ylamino)cyclohexyl)oxy)benzenesulfonamide] (Compound 7)
2- 클로로벤조티아졸 (2- chlorobenzothiazole ; 76.7 μL , 0.59 mmol )이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤젠술폰아마이드 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzenesulfonamide; 79.8 mg, 0.30 mmol) 및 탄산칼륨 (K2CO3; 81.4 mg, 0.59 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=2:3)에 의해 정제하여 17.2 mg (14 %)의 화합물 7을 아이보리색 고체로서 수득하였다. 4 - ((( 1,4 - trans ) -4 - aminocyclohexyl ) oxy)benzenesulfonamide ( 4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzenesulfonamide; 79.8 mg, 0.30 mmol) and potassium carbonate (K 2 CO 3 ; 81.4 mg, 0.59 mmol) were added at ambient temperature. did. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=2:3) to give 17.2 mg (14%) of
1H NMR (CD3OD, 500 MHz) δ 7.82 (d, 2H, J = 8.8 Hz), 7.56 (d, 1H, J = 7.8 Hz), 7.42 (d, 1H, J = 8.1 Hz), 7.24 (m, 1H), 7.05 (d, 2H, J = 8.7 Hz), 7.03 (m, 1H), 4.58 (s, 1H), 4.46 (m, 1H), 3.83 (m, 1H), 2.21 (m, 4H), 1.65 (m, 2H), 1.53 (m, 2H); 13C NMR (CD3OD, 125 MHz) δ 168.3, 162.2, 153.3, 136.5, 131.1, 129.3, 126.9, 122.6, 121.7, 118.8, 116.6, 76.2, 53.6, 31.0, 30.9. 1 H NMR (CD 3 OD, 500 MHz) δ 7.82 (d, 2H, J = 8.8 Hz), 7.56 (d, 1H, J = 7.8 Hz), 7.42 (d, 1H, J = 8.1 Hz), 7.24 ( m, 1H), 7.05 (d, 2H, J = 8.7 Hz), 7.03 (m, 1H), 4.58 (s, 1H), 4.46 (m, 1H), 3.83 (m, 1H), 2.21 (m, 4H) ), 1.65 (m, 2H), 1.53 (m, 2H); 13 C NMR (CD 3 OD, 125 MHz) δ 168.3, 162.2, 153.3, 136.5, 131.1, 129.3, 126.9, 122.6, 121.7, 118.8, 116.6, 76.2, 53.6, 31.0, 30.9.
8. 8. NN -((1,4-트랜스)-4-(4--((1,4-trans)-4-(4- 클로로페녹시Chlorophenoxy )) 사이클로헥실cyclohexyl )-6-)-6- 플루오로벤조[Fluorobenzo[ dd ]티아졸]thiazole -2-아민 [-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-)-4-(4- ChlorophenoxyChlorophenoxy )) cyclohexylcyclohexyl )-6-fluorobenzo[)-6-fluorobenzo[ dd ]thiazol-2-amine] (화합물 8)]thiazol-2-amine] (Compound 8)
2-클로로-6-플루오로벤조티아졸 (2-chloro-6-fluorobenzothiazole; 55 mg, 0.29 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-클로로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-chlorophenoxy)cyclohexan-1-amine; 60.0 mg, 0.27 mmol) 및 탄산칼륨 (K2CO3; 36.8 mg, 0.27 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 26.0 mg (24 %)의 화합물 8을 아이보리색 고체로서 수득하였다.(1,4-trans)-4-(4-chlorophenone) in DMF (1.5 mL) containing 2-chloro-6-fluorobenzothiazole (55 mg, 0.29 mmol). cy)cyclohexan-1-amine ((1,4- trans )-4-(4-chlorophenoxy)cyclohexan-1-amine; 60.0 mg, 0.27 mmol) and potassium carbonate (K 2 CO 3 ; 36.8 mg, 0.27 mmol) ) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 26.0 mg (24%) of compound 8 as an ivory solid.
1H NMR (CDCl3, 500 MHz) δ 7.45 (dd, 1H, J = 8.7, 4.7 Hz), 7.29 (dd, 1H, J = 8.0, 2.1 Hz), 7.22 (d, 2H, J = 8.7 Hz), 7.02 (td, 1H, J = 8.9, 2.1 Hz), 6.83 (d, 2H, J = 8.7 Hz), 5.33 (s, 1H), 4.19 (m, 1H), 3.71 (m, 1H), 2.29 (m, 2H), 2.15 (m, 2H), 1.65 (m, 2H), 1.43 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 165.9, 159.3, 157.4, 156.2, 148.9, 131.2, 131.1, 129.5, 125.9, 119.4, 119.3, 117.5, 113.8, 113.6, 107.8, 107.6, 75.2, 53.4, 30.4, 29.8. 1H NMR (CDCl 3 , 500 MHz) δ 7.45 (dd, 1H, J = 8.7, 4.7 Hz), 7.29 (dd, 1H, J = 8.0, 2.1 Hz), 7.22 (d, 2H, J = 8.7 Hz) , 7.02 (td, 1H, J = 8.9, 2.1 Hz), 6.83 (d, 2H, J = 8.7 Hz), 5.33 (s, 1H), 4.19 (m, 1H), 3.71 (m, 1H), 2.29 ( m, 2H), 2.15 (m, 2H), 1.65 (m, 2H), 1.43 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 165.9, 159.3, 157.4, 156.2, 148.9, 131.2, 131.1, 129.5, 125.9, 119.4, 119.3, 117.5, 113.8, 113.6, 107.8, 107.6, 75.2, 53.4, 30.4, 29.8 .
9. 6-9. 6- 플루오로Fluoro -- NN -((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-]Thiazol-2-amine [6- FluoroFluoro -- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 9)]thiazol-2-amine] (Compound 9)
2-클로로-6-플루오로벤조티아졸 (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 69.0 mg, 0.27 mmol) 및 탄산칼륨 (K2CO3; 73.7 mg, 0.53 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 60.8 mg (56 %)의 화합물 9를 아이보리색 고체로서 수득하였다.(1,4-trans)-4-(4-(tri) in DMF (1.5 mL) containing 2-chloro-6-fluorobenzothiazole (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol) Fluoromethyl)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 69.0 mg, 0.27 mmol) and potassium carbonate (K 2 CO 3 ; 73.7 mg, 0.53 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 60.8 mg (56%) of
1H NMR (CDCl3, 500 MHz) δ 7.53 (d, 2H, J = 8.6 Hz), 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.30 (dd, 1H, J = 8.1, 2.5 Hz), 7.02 (td, 1H, J = 9.0, 2.6 Hz), 6.95 (d, 2H, J = 8.6 Hz), 5.27 (s, 1H), 4.32 (m, 1H), 3.74 (m, 1H), 2.32 (m, 2H), 2.18 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 165.9, 165.9, 160.2, 159.4, 157.5, 148.9, 131.3, 131.2, 127.8, 127.1, 127.1, 127.1, 127.1, 125.6, 123.5, 123.4, 123.1, 122.9, 122.6, 121.3, 119.4, 119.4, 115.7, 113.9, 113.7, 107.8, 107.6, 74.8, 72.9, 53.3, 30.4, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 7.53 (d, 2H, J = 8.6 Hz), 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.30 (dd, 1H, J = 8.1, 2.5 Hz) , 7.02 (td, 1H, J = 9.0, 2.6 Hz), 6.95 (d, 2H, J = 8.6 Hz), 5.27 (s, 1H), 4.32 (m, 1H), 3.74 (m, 1H), 2.32 ( m, 2H), 2.18 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 165.9, 165.9, 160.2, 159.4, 157.5, 148.9, 131.3, 131.2, 127.8, 127.1, 127.1, 127.1, 127.1, 125.6, 123.4, 123.1, 122.9, 122.6, 121.3 , 119.4, 119.4, 115.7, 113.9, 113.7, 107.8, 107.6, 74.8, 72.9, 53.3, 30.4, 29.7.
10. 6-10. 6- 플루오로Fluoro -- NN -((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-]Thiazol-2-amine [6- FluoroFluoro -- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 10)]thiazol-2-amine] (Compound 10)
2-클로로-6-플루오로벤조티아졸 (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 73.2 mg, 0.27 mmol) 및 탄산칼륨 (K2CO3; 73.7 mg, 0.53 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:5)에 의해 정제하여 37.5 mg (33 %)의 화합물 10을 아이보리색 고체로서 수득하였다.(1,4-trans)-4-(4-(tri) in DMF (1.5 mL) containing 2-chloro-6-fluorobenzothiazole (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol) Fluoromethoxy)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 73.2 mg, 0.27 mmol) and potassium carbonate (K 2 CO 3 ; 73.7 mg, 0.53 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:5) to give 37.5 mg (33%) of
1H NMR (CDCl3, 500 MHz) δ 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.29 (dd, 1H, J = 8.2, 2.5 Hz), 7.13 (d, 2H, J = 8.6 Hz), 7.01 (td, 1H, J = 9.0, 2.6 Hz), 6.88 (d, 2H, J = 9.1 Hz), 5.21 (s, 1H), 4.21 (m, 1H), 3.73 (m, 1H), 2.31 (m, 2H), 2.17 (m, 2H), 1.67 (m, 2H), 1.44 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 165.8, 159.4, 157.5, 156.2, 148.9, 142.9, 142.9, 131.3, 131.2, 123.8, 122.6, 121.7, 119.7, 119.5, 119.4, 117.6, 116.9, 113.8, 113.7, 107.8, 107.6, 75.3, 53.4, 30.5, 29.9. 1H NMR (CDCl 3 , 500 MHz) δ 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.29 (dd, 1H, J = 8.2, 2.5 Hz), 7.13 (d, 2H, J = 8.6 Hz) , 7.01 (td, 1H, J = 9.0, 2.6 Hz), 6.88 (d, 2H, J = 9.1 Hz), 5.21 (s, 1H), 4.21 (m, 1H), 3.73 (m, 1H), 2.31 ( m, 2H), 2.17 (m, 2H), 1.67 (m, 2H), 1.44 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 165.8, 159.4, 157.5, 156.2, 148.9, 142.9, 142.9, 131.3, 131.2, 123.8, 122.6, 121.7 , 107.6, 75.3, 53.4, 30.5, 29.9.
11. 4-(((1,4-트랜스)-4-((6-11. 4-(((1,4-trans)-4-((6- 플루오로벤조[Fluorobenzo[ dd ]티아졸]thiazole -2-일)아미노)-2-yl)amino) 사이클로헥실cyclohexyl )옥시)벤조나이트릴 [4-(((1,4-)oxy)benzonitrile [4-(((1,4- transtrans )-4-((6-)-4-((6- Fluorobenzo[Fluorobenzo[ dd ]thiazol]thiazol -2-yl)amino)cyclohexyl)oxy)benzonitrile] (화합물 11)-2-yl)amino)cyclohexyl)oxy)benzonitrile] (Compound 11)
2-클로로-6-플루오로벤조티아졸 (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤조나이트릴 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzonitrile; 57.5 mg, 0.27 mmol) 및 탄산칼륨 (K2CO3; 73.7 mg, 0.53 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:1)에 의해 정제하여 55.2 mg (56 %)의 화합물 11을 아이보리색 고체로서 수득하였다.4-(((1,4-trans)-4-amino in DMF (1.5 mL) containing 2-chloro-6-fluorobenzothiazole (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol) Cyclohexyl)oxy)benzonitrile (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzonitrile; 57.5 mg, 0.27 mmol) and potassium carbonate (K 2 CO 3 ; 73.7 mg, 0.53 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:1) to give 55.2 mg (56%) of
1H NMR (CDCl3, 500 MHz) δ 7.57 (d, 2H, J = 8.9 Hz), 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.29 (dd, 1H, J = 8.2, 2.5 Hz), 7.01 (td, 1H, J = 9.0, 2.6 Hz), 6.93 (d, 2H, J = 8.8 Hz), 5.20 (d, 1H, J = 6.6 Hz), 4.33 (m, 1H), 3.77 (m, 1H), 2.32 (m, 2H), 2.17 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 165.7, 165.6, 161.1, 159.4, 157.5, 149.0, 134.2, 131.3, 131.2, 119.5, 119.4, 119.4, 116.2, 113.8, 113.6, 107.8, 107.6, 103.9, 75.0, 53.1, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 7.57 (d, 2H, J = 8.9 Hz), 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.29 (dd, 1H, J = 8.2, 2.5 Hz) , 7.01 (td, 1H, J = 9.0, 2.6 Hz), 6.93 (d, 2H, J = 8.8 Hz), 5.20 (d, 1H, J = 6.6 Hz), 4.33 (m, 1H), 3.77 (m, 1H), 2.32 (m, 2H), 2.17 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 165.7, 165.6, 161.1, 159.4, 157.5, 134.2, 131.3, 131.2, 119.5, 119.4, 119.4, 116.2, 113.8, 113.8, 107.8, 107.6, 103.9, 75.0, 53.1 , 30.3, 29.7.
12. 6-12. 6- 플루오로Fluoro -- NN -- (( (1,4-트랜스)-4-(4-(1,4-trans)-4-(4- 나이트로페녹시nitrophenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [6--2-amine [6- FluoroFluoro -- NN -((1,4--((1,4- transtrans )-4-(4-nitrophenoxy)cyclohexyl)benzo[)-4-(4-nitrophenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 12)]thiazol-2-amine] (Compound 12)
2-클로로-6-플루오로벤조티아졸 (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-nitrophenoxy)cyclohexan-1-amine; 62.8 mg, 0.27 mmol) 및 탄산칼륨 (K2CO3; 73.7 mg, 0.53 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산:디클로로메탄=1:3:1)에 의해 정제하여 62.6 mg (61 %)의 화합물 12를 밝은 노란색 고체로서 수득하였다.(1,4-trans)-4-(4-nitro Phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-nitrophenoxy)cyclohexan-1-amine; 62.8 mg, 0.27 mmol) and potassium carbonate (K 2 CO 3 ; 73.7 mg, 0.53 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane: dichloromethane=1:3:1) to give 62.6 mg (61%) of
1H NMR (CDCl3, 500 MHz)δ 8.19 (d, 2H, J = 9.3 Hz), 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.29 (dd, 1H, J = 8.1, 2.5 Hz), 7.01 (td, 1H, J = 9.0, 2.6 Hz), 6.94 (d, 2H, J = 9.2 Hz), 5.23 (d, 1H, J = 4.3 Hz), 4.38 (m, 1H), 3.78 (m, 1H), 2.34 (m, 2H), 2.20 (m, 2H), 1.72 (m, 2H), 1.48 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 165.7, 165.7, 162.9, 159.4, 157.5, 148.9, 141.4, 131.3, 131.2, 126.1, 119.5, 119.4, 115.4, 113.8, 113.7, 107.8, 107.6, 75.4, 53.1, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 8.19 (d, 2H, J = 9.3 Hz), 7.45 (dd, 1H, J = 8.8, 4.7 Hz), 7.29 (dd, 1H, J = 8.1, 2.5 Hz) , 7.01 (td, 1H, J = 9.0, 2.6 Hz), 6.94 (d, 2H, J = 9.2 Hz), 5.23 (d, 1H, J = 4.3 Hz), 4.38 (m, 1H), 3.78 (m, 1H), 2.34 (m, 2H), 2.20 (m, 2H), 1.72 (m, 2H), 1.48 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 165.7, 165.7, 162.9, 159.4, 157.5, 148.9, 141.4, 131.3, 131.2, 126.1, 119.5, 119.4, 115.4, 113.8, 113.8, 107.8, 107.6, 75.4, 53.1 , 29.7.
13. 6-13. 6- 플루오로Fluoro -- NN -- (( (1,4-트랜스)-4-(4-((1,4-trans)-4-(4-( 메틸술포닐methylsulfonyl )) 페녹시phenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [6--2-amine [6- FluoroFluoro -- NN -((1,4--((1,4- transtrans )-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 13)]thiazol-2-amine] (Compound 13)
2-클로로-6-플루오로벤조티아졸 (2-chloro-6-fluorobenzothiazole; 100 mg, 0.53 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥산-1-아민 (((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 71.6 mg, 0.27 mmol) 및 탄산칼륨 (K2CO3; 73.7 mg, 0.53 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=3:2)에 의해 정제하여 51.6 mg (46 %)의 화합물 13을 흰색 고체로서 수득하였다.(1,4-trans)-4-(4-(methyl) in DMF (1.5 mL) containing 2-chloro-6-fluorobenzothiazole (100 mg, 0.53 mmol). Sulfonyl) phenoxy) cyclohexan-1-amine (((1,4- trans ) -4- (4- (methylsulfonyl) phenoxy) cyclohexan-1-amine; 71.6 mg, 0.27 mmol) and potassium carbonate (K 2 CO 3 ; 73.7 mg, 0.53 mmol) was added at ambient temperature After stirring at 120° C. for 17 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). Then, the combined organic layers were dried over MgSO 4 and concentrated in vacuo The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=3:2) to give 51.6 mg (46%) of
1H NMR (CDCl3, 500 MHz) δ 7.85 (d, 2H, J = 8.8 Hz), 7.44 (dd, 1H, J = 8.8, 4.7 Hz), 7.28 (dd, 1H, J = 8.1, 2.4 Hz), 7.02 (m, 1H), 7.00 (d, 2H, J = 8.8 Hz), 5.26 (d, 1H, J = 6.0 Hz), 4.36 (m, 1H), 3.77 (m, 1H), 3.03 (s, 3H), 2.32 (m, 2H), 2.18 (m, 2H), 1.70 (m, 2H), 1.47 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 165.7, 165.7, 162.0, 159.4, 157.5, 149.0, 132.2, 131.3, 131.2, 129.7, 119.5, 119.4, 116.0, 113.8, 113.6, 107.8, 107.6, 75.1, 53.1, 45.0, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 7.85 (d, 2H, J = 8.8 Hz), 7.44 (dd, 1H, J = 8.8, 4.7 Hz), 7.28 (dd, 1H, J = 8.1, 2.4 Hz) , 7.02 (m, 1H), 7.00 (d, 2H, J = 8.8 Hz), 5.26 (d, 1H, J = 6.0 Hz), 4.36 (m, 1H), 3.77 (m, 1H), 3.03 (s, 3H), 2.32 (m, 2H), 2.18 (m, 2H), 1.70 (m, 2H), 1.47 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 165.7, 165.7, 162.0, 159.4, 157.5, 149.0, 132.2, 131.3, 131.2, 129.7, 119.5, 119.4, 116.0, 113.8, 113.8, 107.8, 107.6, 75.1, 53.1, 45.0 , 30.3, 29.7.
14. 4-(((1,4-트랜스)-4-((6-14. 4-(((1,4-trans)-4-((6- 플루오로벤조[Fluorobenzo[ dd ]티아졸]thiazole -2-일)아미노)-2-yl)amino) 사이클로헥실cyclohexyl )옥시)벤젠술폰아마이드 [4-(((1,4-)oxy)benzenesulfonamide [4-(((1,4- transtrans )-4-((6-)-4-((6- Fluorobenzo[Fluorobenzo[ dd ]thiazol]thiazol -2-yl)amino)cyclohexyl)oxy)benzenesulfonamide] (화합물 14)-2-yl) amino) cyclohexyl) oxy) benzenesulfonamide] (Compound 14)
2-클로로-6-플루오로벤조티아졸 (2-chloro-6-fluorobenzothiazole; 55.0 mg, 0.29 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤젠술폰아마이드 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzenesulfonamide; 80.0 mg, 0.27 mmol) 및 탄산칼륨 (K2CO3; 36.8 mg, 0.27 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:메탄올=10:1)에 의해 정제하여 17.3 mg (15 %)의 화합물 14를 흰색 고체로서 수득하였다.4-(((1,4-trans)-4-amino in DMF (1.5 mL) containing 2-chloro-6-fluorobenzothiazole (2-chloro-6-fluorobenzothiazole; 55.0 mg, 0.29 mmol) Cyclohexyl)oxy)benzenesulfonamide (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzenesulfonamide; 80.0 mg, 0.27 mmol) and potassium carbonate (K 2 CO 3 ; 36.8 mg, 0.27 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate:methanol=10:1) to give 17.3 mg (15%) of
1H NMR (DMSO-d 6, 500 MHz) δ 8.00 (d, 1H, J = 7.1 Hz), 7.72 (d, 2H, J = 8.8 Hz), 7.58 (dd, 1H, J = 8.7, 2.6 Hz), 7.36 (dd, 1H, J = 8.8, 4.9 Hz), 7.19 (s, 2H), 7.12 (d, 2H, J = 8.9 Hz), 7.03 (td, 1H, J = 9.1, 2.6 Hz), 4.49 (m, 1H), 3.77 (m, 1H), 2.11 (m, 4H), 1.50 (m, 4H); 13C NMR (DMSO-d 6, 125 MHz) δ 165.1, 159.8, 158.1, 156.2, 149.3, 135.9, 131.3, 131.2, 127.7, 118.3, 118.3, 115.4, 112.8, 112.6, 107.9, 107.7, 74.4, 51.8, 29.4, 29.3. 1 H NMR (DMSO- d 6 , 500 MHz) δ 8.00 (d, 1H, J = 7.1 Hz), 7.72 (d, 2H, J = 8.8 Hz), 7.58 (dd, 1H, J = 8.7, 2.6 Hz) , 7.36 (dd, 1H, J = 8.8, 4.9 Hz), 7.19 (s, 2H), 7.12 (d, 2H, J = 8.9 Hz), 7.03 (td, 1H, J = 9.1, 2.6 Hz), 4.49 ( m, 1H), 3.77 (m, 1H), 2.11 (m, 4H), 1.50 (m, 4H); 13 C NMR (DMSO- D 6 , 125 MHz) Δ 165.1, 159.8, 158.1, 156.2, 149.3, 135.9, 131.3, 131.2, 127.7, 118.3, 118.3, 115.4, 112.8, 112.6, 107.9, 107.7, 74.4, 51.8, 29.4 , 29.3.
15. 6-15. 6- 클로로Chloro -- NN -- (( (1,4-트랜스)-4-(4-(1,4-trans)-4-(4- 클로로페녹시Chlorophenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [6--2-amine [6- ChloroChloro -- NN -((1,4--((1,4- transtrans )-4-(4-chlorophenoxy)cyclohexyl)benzo[)-4-(4-chlorophenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 15)]thiazol-2-amine] (Compound 15)
2,6-디클로로벤조티아졸 (2,6-dichlorobenzothiazole; 55.0 mg, 0.27 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-디클로로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-chlorophenoxy)cyclohexan-1-amine; 55.2 mg, 0.24 mmol) 및 탄산칼륨 (K2CO3; 33.7 mg, 0.24 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 20.0 mg (19 %)의 화합물 15를 흰색 고체로서 수득하였다.(1,4-trans)-4-(4-dichlorophenoxy)cyclohexane- (1,4-trans)-4-(4-dichlorophenoxy)cyclohexane- 1-amine ((1,4- trans )-4-(4-chlorophenoxy)cyclohexan-1-amine; 55.2 mg, 0.24 mmol) and potassium carbonate (K 2 CO 3 ; 33.7 mg, 0.24 mmol) at ambient temperature ( ambient temperature). After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 20.0 mg (19%) of
1H NMR (CDCl3, 500 MHz) δ 7.54 (d, 1H, J = 1.9 Hz), 7.42 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 7.22 (d, 2H, J = 9.0 Hz), 6.83 (d, 2H, J = 8.9 Hz), 5.32 (s, 1H), 4.19 (m, 1H), 3.71 (m, 1H), 2.29 (m, 2H), 2.15 (m, 2H), 1.65 (m, 2H), 1.43 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.5, 156.2, 151.2, 131.7, 129.6, 126.9, 126.6, 125.9, 120.6, 119.7, 117.5, 75.1, 53.5, 30.4, 29.8. 1 H NMR (CDCl 3 , 500 MHz) δ 7.54 (d, 1H, J = 1.9 Hz), 7.42 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 7.22 (d, 2H, J = 9.0 Hz), 6.83 (d, 2H, J = 8.9 Hz), 5.32 (s, 1H), 4.19 (m, 1H), 3.71 (m, 1H), 2.29 (m, 2H), 2.15 (m, 2H) , 1.65 (m, 2H), 1.43 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.5, 156.2, 151.2, 131.7, 129.6, 126.9, 126.6, 125.9, 120.6, 119.7, 117.5, 75.1, 53.5, 30.4, 29.8.
16. 6-16. 6- 클로로Chloro -- NN -((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-]Thiazol-2-amine [6- ChloroChloro -- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 16)]thiazol-2-amine] (Compound 16)
2,6-디클로로벤조티아졸 (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 63.5 mg, 0.25 mmol) 및 탄산칼륨 (K2CO3; 67.7 mg, 0.49 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:6)에 의해 정제하여 276.0 mg (73 %)의 화합물 16을 흰색 고체로서 수득하였다.(1,4-trans)-4-(4-(trifluoromethyl)phenoxane in DMF (1.5 mL) containing 2,6-dichlorobenzothiazole (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol) c)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 63.5 mg, 0.25 mmol) and potassium carbonate (K 2 CO 3 ; 67.7 mg , 0.49 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:6) to give 276.0 mg (73%) of
1H NMR (CDCl3, 500 MHz) δ 7.55 (m, 1H), 7.53 (d, 2H, J = 9.8 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 6.95 (d, 2H, J = 8.6 Hz), 5.33 (s, 1H), 4.32 (m, 1H), 3.74 (m, 1H), 2.31 (m, 2H), 2.18 (m, 2H), 1.69 (m, 2H), 1.47 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.5, 160.2, 151.1, 131.7, 127.8, 127.1, 127.1, 127.1, 127.1, 127.0, 126.9, 126.6, 125.6, 123.5, 123.4, 123.2, 122.9, 122.6, 121.3, 120.6, 119.6, 115.7, 74.7, 53.4, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 7.55 (m, 1H), 7.53 (d, 2H, J = 9.8 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 6.95 (d, 2H, J = 8.6 Hz), 5.33 (s, 1H), 4.32 (m, 1H), 3.74 (m, 1H), 2.31 (m, 2H), 2.18 (m, 2H), 1.69 (m, 2H), 1.47 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 166.5, 160.2, 151.1, 131.7, 127.8, 127.1, 127.1, 127.1, 127.1, 127.0, 126.9, 126.6, 125.6, 123.5, 123.2, 123.2, 122.9, 122.6, 121.3, 120.6, 120.6 , 119.6, 115.7, 74.7, 53.4, 30.3, 29.7.
17. 6-17. 6- 클로로Chloro -- NN -((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-]Thiazol-2-amine [6- ChloroChloro -- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 17)]thiazol-2-amine] (Compound 17)
2,6-디클로로벤조티아졸 (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 67.4 mg, 0.25 mmol) 및 탄산칼륨 (K2CO3; 67.7 mg, 0.49 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (디클로로메탄:n-헥산:메탄올=25:5:1)에 의해 정제하여 46.5 mg (43 %)의 화합물 17을 흰색 고체로서 수득하였다.(1,4-trans)-4-(4-(trifluoromethoxy)phenoxy cy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 67.4 mg, 0.25 mmol) and potassium carbonate (K 2 CO 3 ; 67.7 mg , 0.49 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (dichloromethane: n -hexane: methanol=25:5:1) to give 46.5 mg (43%) of
1H NMR (CDCl3, 500 MHz) δ 7.55 (d, 1H, J = 2.0 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 7.13 (d, 2H, J = 8.7 Hz), 6.88 (d, 2H, J = 9.0 Hz), 5.31 (s, 1H), 4.21 (m, 1H), 3.72 (m, 1H), 2.30 (m, 2H), 2.17 (m, 2H), 1.66 (m, 2H), 1.44 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.5, 156.2, 151.2, 143.0, 131.7, 126.9, 126.6, 123.7, 122.6, 121.7, 120.6, 119.7, 117.6, 116.9, 75.3, 53.5, 30.4, 29.8. 1 H NMR (CDCl 3 , 500 MHz) δ 7.55 (d, 1H, J = 2.0 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 7.13 (d, 2H, J = 8.7 Hz), 6.88 (d, 2H, J = 9.0 Hz), 5.31 (s, 1H), 4.21 (m, 1H), 3.72 (m, 1H), 2.30 (m, 2H), 2.17 (m, 2H) , 1.66 (m, 2H), 1.44 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.5, 156.2, 151.2, 143.0, 131.7, 126.9, 126.6, 123.7, 122.6, 121.7, 120.6, 119.7, 117.6, 116.5, 0, 75.4.3, 25.4.3
18. 4-(((1,4-트랜스)-4-((6-18. 4-(((1,4-trans)-4-((6- 클로로벤조[Chlorobenzo[ dd ]티아졸]thiazole -2-일)아미노)-2-yl)amino) 사이클로헥실cyclohexyl )옥시)벤조나이트릴 [4-(((1,4-)oxy)benzonitrile [4-(((1,4- transtrans )-4-((6-)-4-((6- Chlorobenzo[Chlorobenzo[ dd ]thiazol]thiazol -2-yl)amino)cyclohexyl)oxy)benzonitrile] (화합물 18)-2-yl)amino)cyclohexyl)oxy)benzonitrile] (Compound 18)
2,6-디클로로벤조티아졸 (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤조나이트릴 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzonitrile; 52.9 mg, 0.25 mmol) 및 탄산칼륨 (K2CO3; 67.7 mg, 0.49 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 65.1 mg (69 %)의 화합물 18을 흰색 고체로서 수득하였다.4-(((1,4-trans)-4-aminocyclohexyl)oxy) Benzonitrile (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzonitrile; 52.9 mg, 0.25 mmol) and potassium carbonate (K 2 CO 3 ; 67.7 mg, 0.49 mmol) were stirred at ambient temperature (ambient temperature) was added. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 65.1 mg (69%) of
1H NMR (CDCl3, 500 MHz) δ 7.57 (d, 2H, J = 8.8 Hz), 7.54 (d, 1H, J = 1.9 Hz), 7.42 (d, 1H, J = 8.6 Hz), 7.25 (dd, 1H, J = 8.7, 2.0 Hz), 6.93 (d, 2H, J = 8.8 Hz), 5.37 (s, 1H), 4.33 (m, 1H), 3.75 (m, 1H), 2.31 (m, 2H), 2.17 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.4, 161.1, 151.1, 134.2, 131.7, 126.9, 126.6, 120.6, 119.7, 119.3, 116.2, 103.9, 74.9, 53.2, 30.3, 29.6. 1 H NMR (CDCl 3 , 500 MHz) δ 7.57 (d, 2H, J = 8.8 Hz), 7.54 (d, 1H, J = 1.9 Hz), 7.42 (d, 1H, J = 8.6 Hz), 7.25 (dd , 1H, J = 8.7, 2.0 Hz), 6.93 (d, 2H, J = 8.8 Hz), 5.37 (s, 1H), 4.33 (m, 1H), 3.75 (m, 1H), 2.31 (m, 2H) , 2.17 (m, 2H), 1.69 (m, 2H), 1.46 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.4, 161.1, 151.1, 134.2, 131.7, 126.9, 126.6, 120.6, 119.7, 119.3, 116.2, 103.9, 74.9, 53.2, 30.6, 29.6.
19. 6-19. 6- 클로로Chloro -- NN -- (( (1,4-트랜스)-4-(4-(1,4-trans)-4-(4- 나이트로페녹시nitrophenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [6--2-amine [6- ChloroChloro -- NN -((1,4--((1,4- transtrans )-4-(4-nitrophenoxy)cyclohexyl)benzo[)-4-(4-nitrophenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 19)]thiazol-2-amine] (Compound 19)
2,6-디클로로벤조티아졸 (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-nitrophenoxy)cyclohexan-1-amine; 57.9 mg, 0.25 mmol) 및 탄산칼륨 (K2CO3; 67.7 mg, 0.49 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:2)에 의해 정제하여 65.6 mg (66 %)의 화합물 19를 밝은 노란색 고체로서 수득하였다.(1,4-trans)-4-(4-nitrophenoxy)cyclohexane in DMF (1.5 mL) containing 2,6-dichlorobenzothiazole (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol). -1-amine ((1,4- trans )-4-(4-nitrophenoxy)cyclohexan-1-amine; 57.9 mg, 0.25 mmol) and potassium carbonate (K 2 CO 3 ; 67.7 mg, 0.49 mmol) were added at ambient temperature. (ambient temperature). After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:2) to give 65.6 mg (66%) of
1H NMR (CDCl3, 500 MHz) δ 8.19 (d, 2H, J = 9.2 Hz), 7.54 (d, 1H, J = 1.9 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 6.94 (d, 2H, J = 9.2 Hz), 5.33 (s, 1H), 4.38 (m, 1H), 3.77 (m, 1H), 2.33 (m, 2H), 2.20 (m, 2H), 1.72 (m, 2H), 1.48 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.3, 162.9, 151.2, 141.5, 131.7, 127.0, 126.6, 126.2, 120.6, 119.7, 115.4, 75.4, 53.1, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 8.19 (d, 2H, J = 9.2 Hz), 7.54 (d, 1H, J = 1.9 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m , 1H), 6.94 (d, 2H, J = 9.2 Hz), 5.33 (s, 1H), 4.38 (m, 1H), 3.77 (m, 1H), 2.33 (m, 2H), 2.20 (m, 2H) , 1.72 (m, 2H), 1.48 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.3, 162.9, 151.2, 141.5, 131.7, 127.0, 126.6, 126.2, 120.6, 119.7, 115.4, 75.4, 53.1, 30.3, 29.7.
*20. 6- 클로로 - N - ( (1,4-트랜스)-4-(4-( 메틸술포닐 ) 페녹시 ) 사이클로헥실 ) 벤조[ d ]티아졸 -2-아민 [6- Chloro - N -((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine] (화합물 20) * 20. 6- Chloro - N - ( (1,4-trans)-4-(4-( methylsulfonyl ) phenoxy ) cyclohexyl ) benzo[ d ]thiazol -2-amine [6- Chloro - N -((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ d ]thiazol-2-amine] (Compound 20)
2,6-디클로로벤조티아졸 (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 66.0 mg, 0.25 mmol) 및 탄산칼륨 (K2CO3; 67.7 mg, 0.49 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:디클로로메탄:메탄올=15:15:1)에 의해 정제하여 28.4 mg (26 %)의 화합물 20을 흰색 고체로서 수득하였다.(1,4-trans)-4-(4-(methylsulfonyl)phenoxy )cyclohexan-1-amine ((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 66.0 mg, 0.25 mmol) and potassium carbonate (K 2 CO 3 ; 67.7 mg, 0.49 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate:dichloromethane:methanol=15:15:1) to give 28.4 mg (26%) of
1H NMR (CDCl3, 500 MHz) δ 7.86 (d, 2H, J = 8.9 Hz), 7.55 (d, 1H, J = 1.9 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m, 1H), 7.01 (d, 2H, J = 8.9 Hz), 5.14 (s, 1H), 4.38 (m, 1H), 3.78 (m, 1H), 3.03 (s, 3H), 2.33 (m, 2H), 2.20 (m, 2H), 1.71 (m, 2H), 1.48 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.2, 162.0, 151.2, 132.3, 131.8, 129.8, 127.0, 126.6, 120.6, 119.8, 116.0, 75.0, 53.2, 45.0, 30.3, 29.6. 1 H NMR (CDCl 3 , 500 MHz) δ 7.86 (d, 2H, J = 8.9 Hz), 7.55 (d, 1H, J = 1.9 Hz), 7.43 (d, 1H, J = 8.6 Hz), 7.25 (m , 1H), 7.01 (d, 2H, J = 8.9 Hz), 5.14 (s, 1H), 4.38 (m, 1H), 3.78 (m, 1H), 3.03 (s, 3H), 2.33 (m, 2H) , 2.20 (m, 2H), 1.71 (m, 2H), 1.48 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 166.2, 162.0, 151.2, 132.3, 131.8, 129.8, 127.0, 126.6, 120.6, 119.8, 116.0, 75.0, 53.2, 45.0, 30.6.3, 29.6.
21. 4-(((1,4-트랜스)-4-((6-21. 4-(((1,4-trans)-4-((6- 클로로벤조[Chlorobenzo[ dd ]티아졸]thiazole -2-일)아미노)-2-yl)amino) 사이클로헥실cyclohexyl )옥시)벤젠술폰아마이드 [4-(((1,4-)oxy)benzenesulfonamide [4-(((1,4- transtrans )-4-((6-)-4-((6- Chlorobenzo[Chlorobenzo[ dd ]thiazol]thiazol -2-yl)amino)cyclohexyl)oxy)benzenesulfonamide] (화합물 21)-2-yl) amino) cyclohexyl) oxy) benzenesulfonamide] (Compound 21)
2,6-디클로로벤조티아졸 (2,6-dichlorobenzothiazole; 100.0 mg, 0.49 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥신)옥시)벤젠술폰아마이드 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzenesulfonamide; 66.2 mg, 0.25 mmol) 및 탄산칼륨 (K2CO3; 67.7 mg, 0.49 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=3:2)에 의해 정제하여 42.7 mg (40 %)의 화합물 21을 아이보리색 고체로서 수득하였다.4-(((1,4-trans)-4-aminocyclohexyne)oxy) Benzenesulfonamide (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzenesulfonamide; 66.2 mg, 0.25 mmol) and potassium carbonate (K 2 CO 3 ; 67.7 mg, 0.49 mmol) were prepared at ambient temperature (ambient temperature). temperature) was added. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=3:2) to give 42.7 mg (40%) of
1H NMR (DMSO-d 6, 500 MHz) δ 8.14 (d, 1H, J = 6.9 Hz), 7.77 (s, 1H), 7.73 (d, 2H, J = 8.5 Hz), 7.36 (d, 1H, J = 8.5 Hz), 7.22 (m, 1H), 7.19 (s, 2H), 7.12 (d, 2H, J = 8.5 Hz), 4.49 (m, 1H), 3.78 (m, 1H), 2.10 (m, 4H), 1.51 (m, 4H); 13C NMR (DMSO-d 6, 125 MHz) δ 165.8, 159.8, 151.6, 135.9, 131.9, 127.7, 125.6, 124.5, 120.5, 118.8, 115.4, 74.4, 51.9, 29.4, 29.2. 1 H NMR (DMSO- d 6 , 500 MHz) δ 8.14 (d, 1H, J = 6.9 Hz), 7.77 (s, 1H), 7.73 (d, 2H, J = 8.5 Hz), 7.36 (d, 1H, J = 8.5 Hz), 7.22 (m, 1H), 7.19 (s, 2H), 7.12 (d, 2H, J = 8.5 Hz), 4.49 (m, 1H), 3.78 (m, 1H), 2.10 (m, 4H), 1.51 (m, 4H); 13 C NMR (DMSO- d 6 , 125 MHz) δ 165.8, 159.8, 151.6, 135.9, 131.9, 127.7, 125.6, 124.5, 120.5, 118.8, 115.4, 74.4, 51.9, 29.4, 29.2.
22. 22. NN -((1,4-트랜스)-4-(4--((1,4-trans)-4-(4- 클로로페녹시Chlorophenoxy )) 사이클로헥실cyclohexyl )-6-)-6- (트리플루오로메틸)벤조[(trifluoromethyl)benzo[ dd ]티아졸]thiazole -2-아민 [-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-)-4-(4- ChlorophenoxyChlorophenoxy )) cyclohexylcyclohexyl )-6-(trifluoromethyl)benzo[)-6-(trifluoromethyl)benzo[ dd ]thiazol-2-amine] (화합물 22)]thiazol-2-amine] (Compound 22)
2-클로로-6-트리플루오로메틸벤조티아졸 (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-클로로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-chlorophenoxy)cyclohexan-1-amine; 52.1 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 29.0 mg, 0.21 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 100 ℃에서 5시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=2:1)에 의해 정제하여 31.4 mg (35 %)의 화합물 22를 흰색 고체로서 수득하였다.(1,4-trans)-4-(4- Chlorophenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-chlorophenoxy)cyclohexan-1-amine; 52.1 mg, 0.23 mmol) and potassium carbonate (K 2 CO 3 ; 29.0 mg, 0.21 mmol) was added at ambient temperature. After stirring at 100 °C for 5 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=2:1) to give 31.4 mg (35%) of
1H NMR (CDCl3, 500 MHz) δ 7.85 (s, 1H), 7.57 (d, 1H, J = 8.6 Hz), 7.54 (d, 1H, J = 8.6 Hz), 7.23 (d, 2H, J = 8.9 Hz), 6.83 (d, 2H, J = 8.9 Hz), 5.81 (s, 1H), 4.20 (m, 1H), 3.74 (m, 1H), 2.30 (m, 2H), 2.16 (m, 2H), 1.66 (m, 2H), 1.47 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 168.3, 156.2, 154.6, 130.4, 129.6, 127.8, 126.0, 125.7, 124.3, 124.0, 123.8, 123.6, 123.5, 123.5, 121.4, 118.6, 118.5, 118.4, 118.4, 118.4, 117.5, 75.0, 53.8, 30.2, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 7.85 (s, 1H), 7.57 (d, 1H, J = 8.6 Hz), 7.54 (d, 1H, J = 8.6 Hz), 7.23 (d, 2H, J = 8.6 Hz) 8.9 Hz), 6.83 (d, 2H, J = 8.9 Hz), 5.81 (s, 1H), 4.20 (m, 1H), 3.74 (m, 1H), 2.30 (m, 2H), 2.16 (m, 2H) , 1.66 (m, 2H), 1.47 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 168.3, 156.2, 154.6, 130.4, 129.6, 127.8, 126.0, 125.7, 124.3, 124.0, 123.8, 123.6, 123.5, 123.5, 121.4, 118.5, 118.4, 118.4, 118.4, 118.4, 118.4 , 117.5, 75.0, 53.8, 30.2, 29.7.
23. 6-(23. 6 - ( 트리플루오로메틸trifluoromethyl )-)- NN -((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-(]Thiazol-2-amine [6-( TrifluoromethylTrifluoromethyl )-)- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 23)]thiazol-2-amine] (Compound 23)
2-클로로-6-트리플루오로메틸벤조티아졸 (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 59.9 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 29.0 mg, 0.21 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 100 ℃에서 5시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (디클로로메탄:n-헥산:메탄올=5:20:1)에 의해 정제하여 25.1 mg (26 %)의 화합물 23을 흰색 폼으로서 수득하였다.(1,4-trans)-4-(4- (trifluoromethyl)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 59.9 mg, 0.23 mmol) and potassium carbonate ( K 2 CO 3 ; 29.0 mg, 0.21 mmol) was added at ambient temperature. After stirring at 100 °C for 5 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (dichloromethane: n -hexane: methanol=5:20:1) to give 25.1 mg (26%) of
1H NMR (CDCl3, 500 MHz) δ 7.85 (s, 1H), 7.57 (m, 2H), 7.54 (d, 2H, J = 8.0 Hz), 6.96 (d, 2H, J = 8.2 Hz), 5.82 (s, 1H), 4.34 (m, 1H), 3.78 (m, 1H), 2.33 (m, 2H), 2.20 (m, 2H), 1.71 (m, 2H), 1.51 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 168.2, 160.2, 154.2, 130.2, 127.8, 127.8, 127.2, 127.1, 127.1, 127.1, 125.6, 125.6, 124.5, 124.2, 123.9, 123.7, 123.6, 123.6, 123.6, 123.5, 123.4, 123.2, 123.0, 122.7, 121.3, 121.3, 118.6, 118.5, 118.5, 118.5, 118.4, 115.7, 74.5, 53.7, 30.1, 29.6. 1H NMR (CDCl 3 , 500 MHz) δ 7.85 (s, 1H), 7.57 (m, 2H), 7.54 (d, 2H, J = 8.0 Hz), 6.96 (d, 2H, J = 8.2 Hz), 5.82 (s, 1H), 4.34 (m, 1H), 3.78 (m, 1H), 2.33 (m, 2H), 2.20 (m, 2H), 1.71 (m, 2H), 1.51 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 168.2, 160.2, 154.2, 130.2, 127.8, 127.8, 127.2, 127.1, 127.1, 127.1, 125.6, 124.5, 124.2, 123.7, 123.7, 123.6, 123.6, 123.6, 123.5, 123.5 , 123.4, 123.2, 123.0, 122.7, 121.3, 121.3, 118.6, 118.5, 118.5, 118.5, 118.4, 115.7, 74.5, 53.7, 30.1, 29.6.
24. 24. NN -((1,4-트랜스)-4-(4-(-((1,4-trans)-4-(4-( 트리플루오로메톡시trifluoromethoxy )) 페녹시phenoxy )) 사이클로헥실cyclohexyl )-6-(트리플루오로메틸)벤조[)-6-(trifluoromethyl)benzo[ dd ]티아졸-2-아민 [N-((1,4-]thiazol-2-amine [N-((1,4- transtrans )-4-(4-(Trifluoromethoxy)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[)-4-(4-(Trifluoromethoxy)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ dd ]thiazol-2-amine] (화합물 24)]thiazol-2-amine] (Compound 24)
2-클로로-6-트리플루오로메틸벤조티아졸 (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 63.5 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 29.0 mg, 0.21 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 100 ℃에서 5시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 13.0 mg (13 %)의 화합물 24를 흰색 고체로서 수득하였다.(1,4-trans)-4-(4- (trifluoromethoxy)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 63.5 mg, 0.23 mmol) and potassium carbonate ( K 2 CO 3 ; 29.0 mg, 0.21 mmol) was added at ambient temperature. After stirring at 100 °C for 5 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 13.0 mg (13%) of
1H NMR (CDCl3, 500 MHz) δ 7.85 (s, 1H), 7.58 (d, 1H, J = 8.8 Hz), 7.56 (d, 1H, J = 8.7 Hz), 7.14 (d, 2H, J = 8.5 Hz), 6.89 (d, 2H, J = 9.1 Hz), 4.25 (m, 1H), 3.75 (m, 1H), 2.31 (m, 2H), 2.19 (m, 2H), 1.70 (m, 2H), 1.51 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 168.3, 156.1, 153.6, 143.0, 143.0, 129.8, 127.8, 125.6, 124.6, 124.4, 124.1, 123.8, 123.8, 123.8, 123.7, 123.7, 123.4, 122.7, 121.7, 121.3, 119.7, 118.6, 118.6, 118.5, 118.5, 118.4, 117.6, 116.9, 75.0, 53.9, 30.0, 29.6. 1 H NMR (CDCl 3 , 500 MHz) δ 7.85 (s, 1H), 7.58 (d, 1H, J = 8.8 Hz), 7.56 (d, 1H, J = 8.7 Hz), 7.14 (d, 2H, J = 8.5 Hz), 6.89 (d, 2H, J = 9.1 Hz), 4.25 (m, 1H), 3.75 (m, 1H), 2.31 (m, 2H), 2.19 (m, 2H), 1.70 (m, 2H) , 1.51 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 168.3, 156.1, 153.6, 143.0, 129.8, 127.8, 125.6, 124.6, 124.4, 124.1, 123.8, 123.8, 123.8, 123.7, 123.7, 123.4, 122.7, 121.7, 121.3 , 119.7, 118.6, 118.6, 118.5, 118.5, 118.4, 117.6, 116.9, 75.0, 53.9, 30.0, 29.6.
25. 4-(((1,4-트랜스)-4-((6-25. 4-(((1,4-trans)-4-((6- (트리플루오로메틸)벤조[(trifluoromethyl)benzo[ dd ]티아졸]thiazole -2-일)아미노)사이클로헥실)옥시)벤조나이트릴 [4-(((1,4--2-yl)amino)cyclohexyl)oxy)benzonitrile [4-(((1,4- transtrans )-4-((6-(Trifluoromethyl)benzo[)-4-((6-(Trifluoromethyl)benzo[ dd ]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile] (화합물 25)]thiazol-2-yl)amino)cyclohexyl)oxy)benzonitrile] (Compound 25)
2-클로로-6-트리플루오로메틸벤조티아졸 (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤조나이트릴 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzonitrile; 50.1 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 29.0 mg, 0.21 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 100 ℃에서 5시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:2)에 의해 정제하여 57.2 mg (65 %)의 화합물 25를 흰색 고체로서 수득하였다.4-(((1,4-trans)-4 in DMF (1.5 mL) containing 2-chloro-6-trifluoromethylbenzothiazole (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol) -aminocyclohexyl)oxy)benzonitrile (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzonitrile; 50.1 mg, 0.23 mmol) and potassium carbonate (K 2 CO 3 ; 29.0 mg, 0.21 mmol) was added at ambient temperature. After stirring at 100 °C for 5 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:2) to give 57.2 mg (65%) of
1H NMR (CDCl3, 500 MHz) δ 7.84 (s, 1H), 7.57 (m, 3H), 7.54 (d, 1H, J = 8.7 Hz), 6.94 (d, 2H, J = 8.8 Hz), 5.77 (s, 1H), 4.35 (m, 1H), 3.79 (m, 1H), 2.33 (m, 2H), 2.19 (m, 2H), 1.71 (m, 2H), 1.51 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 168.1, 161.1, 154.5, 134.2, 130.4, 127.8, 125.7, 124.4, 124.1, 123.9, 123.6, 123.6, 123.5, 123.5, 123.5, 121.3, 119.3, 118.7, 118.5, 118.5, 118.4, 118.4, 116.2, 104.0, 74.7, 53.5, 30.1, 29.5. 1H NMR (CDCl 3 , 500 MHz) δ 7.84 (s, 1H), 7.57 (m, 3H), 7.54 (d, 1H, J = 8.7 Hz), 6.94 (d, 2H, J = 8.8 Hz), 5.77 (s, 1H), 4.35 (m, 1H), 3.79 (m, 1H), 2.33 (m, 2H), 2.19 (m, 2H), 1.71 (m, 2H), 1.51 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 168.1, 161.1, 154.5, 134.2, 130.4, 127.8, 125.7, 124.4, 124.1, 123.9, 123.6, 123.6, 123.5, 123.5, 123.5, 121.3, 119.3, 118.7, 118.5, 118.5, 118.5, 118.5 , 118.4, 118.4, 116.2, 104.0, 74.7, 53.5, 30.1, 29.5.
26. 26. NN -((1,4-트랜스)-4-(4--((1,4-trans)-4-(4- 나이트로페녹시nitrophenoxy )) 사이클로헥실cyclohexyl )-6-)-6- (트리플루오로메틸)벤조[(trifluoromethyl)benzo[ dd ]티아졸]thiazole -2-아민 [-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-)-4-(4- NitrophenoxyNitrophenoxy )) cyclohexylcyclohexyl )-6-(trifluoromethyl)benzo[)-6-(trifluoromethyl)benzo[ dd ]thiazol-2-amine] (화합물 26)]thiazol-2-amine] (Compound 26)
2-클로로-6-트리플루오로메틸벤조티아졸 (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-nitrophenoxy)cyclohexan-1-amine; 54.6 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 29.0 mg, 0.21 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 100 ℃에서 5시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 44.7 mg (49 %)의 화합물 26을 노란색 고체로서 수득하였다.(1,4-trans)-4-(4- Nitrophenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-nitrophenoxy)cyclohexan-1-amine; 54.6 mg, 0.23 mmol) and potassium carbonate (K 2 CO 3 ; 29.0 mg , 0.21 mmol) was added at ambient temperature. After stirring at 100 °C for 5 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 44.7 mg (49%) of
1H NMR (CDCl3, 500 MHz) δ 8.19 (d, 2H, J = 9.2 Hz), 7.85 (s, 1H), 7.58 (d, 1H, J = 8.5 Hz), 7.55 (d, 1H, J = 8.6 Hz), 6.95 (d, 2H, J = 9.2 Hz), 4.41 (m, 1H), 3.81 (m, 1H), 2.35 (m, 2H), 2.22 (m, 2H), 1.74 (m, 2H), 1.53 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 168.1, 162.9, 154.3, 141.5, 130.3, 127.8, 126.2, 125.6, 124.5, 124.2, 124.0, 123.7, 123.6, 123.6, 123.6, 123.6, 123.5, 121.3, 118.6, 118.5, 118.5, 118.4, 118.4, 115.4, 75.2, 53.5, 30.0, 29.5. 1 H NMR (CDCl 3 , 500 MHz) δ 8.19 (d, 2H, J = 9.2 Hz), 7.85 (s, 1H), 7.58 (d, 1H, J = 8.5 Hz), 7.55 (d, 1H, J = 8.6 Hz), 6.95 (d, 2H, J = 9.2 Hz), 4.41 (m, 1H), 3.81 (m, 1H), 2.35 (m, 2H), 2.22 (m, 2H), 1.74 (m, 2H) , 1.53 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 168.1, 162.9, 154.3, 141.5, 130.3, 127.8, 126.2, 125.6, 124.5, 124.2, 124.0, 123.7, 123.6, 123.6, 123.6, 123.6, 123.5, 121.3, 118.6, 118.5 , 118.5, 118.4, 118.4, 115.4, 75.2, 53.5, 30.0, 29.5.
27. 27. NN -((1,4-트랜스)-4-(4-(-((1,4-trans)-4-(4-( 메틸술포닐methylsulfonyl )) 페녹시phenoxy )) 사이클로헥실cyclohexyl )-6-)-6- (트리플루오로메틸)벤조[(trifluoromethyl)benzo[ dd ]티아졸]thiazole -2-아민 [-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[)-4-(4-(Methylsulfonyl)phenoxy)cyclohexyl)-6-(trifluoromethyl)benzo[ dd ]thiazol-2-amine] (화합물 27)]thiazol-2-amine] (Compound 27)
2-클로로-6-트리플루오로메틸벤조티아졸 (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 62.0 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 29.0 mg, 0.21 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 100 ℃에서 5시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=2:1)에 의해 정제하여 40.5 mg (41 %)의 화합물 27을 흰색 고체로서 수득하였다.(1,4-trans)-4-(4- (methylsulfonyl)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 62.0 mg, 0.23 mmol) and potassium carbonate (K 2 CO 3 ; 29.0 mg, 0.21 mmol) was added at ambient temperature. After stirring at 100 °C for 5 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=2:1) to give 40.5 mg (41%) of
1H NMR (CDCl3, 500 MHz) δ 7.86 (d, 2H, J = 9.0 Hz), 7.84 (s, 1H), 7.58 (d, 1H, J = 8.5 Hz), 7.55 (d, 1H, J = 8.6 Hz), 7.01 (d, 2H, J = 8.7 Hz), 4.39 (m, 1H), 3.79 (m, 1H), 3.04 (s, 3H), 2.32 (m, 2H), 2.20 (m, 2H), 1.72 (m, 2H), 1.54 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 168.2, 161.9, 153.8, 132.3, 130.0, 129.8, 127.8, 125.6, 124.5, 124.3, 124.0, 123.8, 123.7, 123.7, 123.7, 123.6, 123.4, 121.3, 118.5, 118.5, 118.5, 118.5, 116.0, 74.7, 53.6, 45.0, 29.9, 29.4. 1H NMR (CDCl 3 , 500 MHz) δ 7.86 (d, 2H, J = 9.0 Hz), 7.84 (s, 1H), 7.58 (d, 1H, J = 8.5 Hz), 7.55 (d, 1H, J = 8.6 Hz), 7.01 (d, 2H, J = 8.7 Hz), 4.39 (m, 1H), 3.79 (m, 1H), 3.04 (s, 3H), 2.32 (m, 2H), 2.20 (m, 2H) , 1.72 (m, 2H), 1.54 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 168.2, 161.9, 153.8, 130.0, 129.8, 127.8, 125.6, 124.5, 124.3, 124.0, 123.8, 123.7, 123.7, 123.7, 123.6, 123.4, 121.3, 118.5, 118.5 , 118.5, 118.5, 116.0, 74.7, 53.6, 45.0, 29.9, 29.4.
28. 4-(((1,4-트랜스)-4-((6-28. 4-(((1,4-trans)-4-((6- (트리플루오로메틸)벤조[(trifluoromethyl)benzo[ dd ]티아졸]thiazole -2-일)아미노)사이클로헥실)옥시)벤젠술폰아마이드 [4-(((1,4--2-yl)amino)cyclohexyl)oxy)benzenesulfonamide [4-(((1,4- transtrans )-4-((6-(Trifluoromethyl)benzo[)-4-((6-(Trifluoromethyl)benzo[ dd ]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide] (화합물 28)]thiazol-2-yl)amino)cyclohexyl)oxy)benzenesulfonamide] (Compound 28)
2-클로로-6-트리플루오로메틸벤조티아졸 (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤젠술폰아마이드 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzenesulfonamide; 62.0 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 29.0 mg, 0.21 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 100 ℃에서 5시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=2:1)에 의해 정제하여 31.5 mg (32 %)의 화합물 28을 흰색 고체로서 수득하였다.4-(((1,4-trans)-4 in DMF (1.5 mL) containing 2-chloro-6-trifluoromethylbenzothiazole (2-chloro-6-trifluoromethylbenzothiazole; 50.0 mg, 0.21 mmol) -Aminocyclohexyl)oxy)benzenesulfonamide (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzenesulfonamide; 62.0 mg, 0.23 mmol) and potassium carbonate (K 2 CO 3 ; 29.0 mg, 0.21 mmol) was added at ambient temperature. After stirring at 100 °C for 5 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=2:1) to give 31.5 mg (32%) of
1H NMR (DMSO-d 6, 500 MHz) δ 8.41 (d, 1H, J = 6.0 Hz), 8.11 (s, 1H), 7.73 (d, 2H, J = 7.4 Hz), 7.51 (m, 2H), 7.19 (s, 2H), 7.12 (d, 2H, J = 7.4 Hz), 4.50 (m, 1H), 3.84 (m, 1H), 2.12 (m, 4H), 1.53 (m, 4H); 13C NMR (DMSO-d 6, 125 MHz) δ 167.8, 159.8, 155.7, 135.9, 130.9, 128.1, 127.7, 125.9, 123.8, 122.7, 121.7, 121.3, 121.1, 120.8, 120.6, 118.5, 117.7, 115.4, 74.4, 52.0, 29.4, 29.2. 1 H NMR (DMSO- d 6 , 500 MHz) δ 8.41 (d, 1H, J = 6.0 Hz), 8.11 (s, 1H), 7.73 (d, 2H, J = 7.4 Hz), 7.51 (m, 2H) , 7.19 (s, 2H), 7.12 (d, 2H, J = 7.4 Hz), 4.50 (m, 1H), 3.84 (m, 1H), 2.12 (m, 4H), 1.53 (m, 4H); 13 C NMR (DMSO- D 6 , 125 MHz) Δ 167.8, 159.8, 155.7, 135.9, 130.9, 128.1, 127.7, 125.9, 123.8, 122.7, 121.7, 121.3, 121.1, 120.8, 120.6, 118.5, 117.7, 115.4, 74.4 , 52.0, 29.4, 29.2.
29. 29. NN -((1,4-트랜스)-4-(4--((1,4-trans)-4-(4- 클로로페녹시Chlorophenoxy )) 사이클로헥실cyclohexyl )-6-)-6- 나이트로벤조[nitrobenzo[ dd ]티아졸]thiazole -2-아민 [-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-)-4-(4- ChlorophenoxyChlorophenoxy )) cyclohexylcyclohexyl )-6-nitrobenzo[)-6-nitrobenzo[ dd ]thiazol-2-amine] (화합물 29)]thiazol-2-amine] (Compound 29)
2-클로로-6-나이트로벤조티아졸 (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-클로로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-chlorophenoxy)cyclohexan-1-amine; 73.6 mg, 0.33 mmol) 및 탄산칼륨 (K2CO3; 45.0 mg, 0.33 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 1시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:1)에 의해 정제하여 47.6 mg (36 %)의 화합물 29를 노란색 고체로서 수득하였다.(1,4-trans)-4-(4-chlorophenone) in DMF (1.5 mL) containing 2-chloro-6-nitrobenzothiazole (70.0 mg, 0.33 mmol) cy)cyclohexan-1-amine ((1,4- trans )-4-(4-chlorophenoxy)cyclohexan-1-amine; 73.6 mg, 0.33 mmol) and potassium carbonate (K 2 CO 3 ; 45.0 mg, 0.33 mmol) ) was added at ambient temperature. After stirring for 1 hour, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:1) to give 47.6 mg (36%) of compound 29 as a yellow solid.
1H NMR (CDCl3, 500 MHz) δ 8.49 (d, 1H, J = 2.2 Hz), 8.20 (dd, 1H, J = 8.9, 2.3 Hz), 7.52 (d, 1H, J = 8.9 Hz), 7.22 (d, 2H, J = 9.0 Hz), 6.83 (d, 2H, J = 8.9 Hz), 4.22 (m, 1H), 3.77 (m, 1H), 2.30 (m, 2H), 2.18 (m, 2H), 1.68 (m, 2H), 1.51 (m, 2H); 13C NMR (DMSO-d 6, 125 MHz) δ 170.1, 156.5, 156.1, 142.3, 130.2, 129.6, 126.0, 122.8, 117.8, 117.6, 117.5, 74.7, 54.2, 29.9, 29.6. 1H NMR (CDCl 3 , 500 MHz) δ 8.49 (d, 1H, J = 2.2 Hz), 8.20 (dd, 1H, J = 8.9, 2.3 Hz), 7.52 (d, 1H, J = 8.9 Hz), 7.22 (d, 2H, J = 9.0 Hz), 6.83 (d, 2H, J = 8.9 Hz), 4.22 (m, 1H), 3.77 (m, 1H), 2.30 (m, 2H), 2.18 (m, 2H) , 1.68 (m, 2H), 1.51 (m, 2H); 13 C NMR (DMSO- d 6 , 125 MHz) δ 170.1, 156.5, 156.1, 142.3, 130.2, 129.6, 126.0, 122.8, 117.8, 117.6, 117.5, 74.7, 54.2, 29.9, 29.6.
30. 6-나이트로-30. 6-Nitro- NN -((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-Nitro-]Thiazol-2-amine [6-Nitro- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 30)]thiazol-2-amine] (Compound 30)
2-클로로-6-나이트로벤조티아졸 (2-chloro-6-nitrobenzothiazole; 50.0 mg, 0.23 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 60.4 mg, 0.23 mmol) 및 탄산칼륨 (K2CO3; 32.2 mg, 0.23 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 1시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:4)에 의해 정제하여 77.2 mg (76 %)의 화합물 30을 노란색 폼으로서 수득하였다.(1,4-trans)-4-(4-(tri) in DMF (1.5 mL) containing 2-chloro-6-nitrobenzothiazole (2-chloro-6-nitrobenzothiazole; 50.0 mg, 0.23 mmol) Fluoromethyl)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 60.4 mg, 0.23 mmol) and potassium carbonate (K 2 CO 3 ; 32.2 mg, 0.23 mmol) was added at ambient temperature. After stirring for 1 hour, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:4) to give 77.2 mg (76%) of
1H NMR (CDCl3, 500 MHz) δ 8.51 (d, 1H, J = 2.1 Hz), 8.21 (dd, 1H, J = 9.0, 2.1 Hz), 7.54 (d, 2H, J = 8.3 Hz), 7.53 (d, 1H, J = 8.7 Hz), 6.96 (d, 2H, J = 8.6 Hz), 5.66 (s, 1H), 4.35 (m, 1H), 3.83 (m, 1H), 2.34 (m, 2H), 2.21 (m, 2H), 1.72 (m, 2H), 1.52 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 170.0, 160.1, 157.8, 142.2, 130.9, 127.7, 127.2, 127.1, 127.1, 127.1, 125.6, 123.5, 123.4, 123.3, 123.0, 122.7, 122.7, 121.3, 118.3, 117.5, 115.7, 74.5, 53.7, 30.1, 29.6. 1 H NMR (CDCl 3 , 500 MHz) δ 8.51 (d, 1H, J = 2.1 Hz), 8.21 (dd, 1H, J = 9.0, 2.1 Hz), 7.54 (d, 2H, J = 8.3 Hz), 7.53 (d, 1H, J = 8.7 Hz), 6.96 (d, 2H, J = 8.6 Hz), 5.66 (s, 1H), 4.35 (m, 1H), 3.83 (m, 1H), 2.34 (m, 2H) , 2.21 (m, 2H), 1.72 (m, 2H), 1.52 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 170.0, 160.1, 157.8, 142.2, 130.9, 127.7, 127.2, 127.1, 127.1, 127.1, 125.6, 123.5, 123.4, 123.3, 123.0, 122.7, 122.7, 121.3, 118.3, 117.5 , 115.7, 74.5, 53.7, 30.1, 29.6.
31. 6-나이트로-31. 6-Nitro- NN -((1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-Nitro-]Thiazol-2-amine [6-Nitro- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 31)]thiazol-2-amine] (Compound 31)
2-클로로-6-나이트로벤조티아졸 (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메톡시)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 89.7 mg, 0.33 mmol) 및 탄산칼륨 (K2CO3; 45.0 mg, 0.33 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 1시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:1)에 의해 정제하여 80.5 mg (54 %)의 화합물 31을 노란색 고체로서 수득하였다.(1,4-trans)-4-(4-(tri) in DMF (1.5 mL) containing 2-chloro-6-nitrobenzothiazole (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol) Fluoromethoxy)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethoxy)phenoxy)cyclohexan-1-amine; 89.7 mg, 0.33 mmol) and potassium carbonate (K 2 CO 3 ; 45.0 mg, 0.33 mmol) was added at ambient temperature. After stirring for 1 hour, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:1) to give 80.5 mg (54%) of
1H NMR (CDCl3, 500 MHz) δ 8.51 (d, 1H, J = 2.2 Hz), 8.22 (dd, 1H, J = 9.0, 2.3 Hz), 7.54 (d, 1H, J = 8.9 Hz), 7.13 (d, 2H, J = 8.9 Hz), 6.89 (d, 2H, J = 9.1 Hz), 4.26 (m, 1H), 3.79 (m, 1H), 2.32 (m, 2H), 2.20 (m, 2H), 1.70 (m, 2H), 1.54 (m, 2H); 13C NMR (DMSO-d 6, 125 MHz) δ 169.9, 156.0, 154.4, 143.0, 143.0, 142.7, 129.1, 123.7, 123.2, 122.7, 121.7, 119.6, 117.8, 117.6, 117.5, 116.9, 74.6, 54.6, 29.6, 29.3. 1 H NMR (CDCl 3 , 500 MHz) δ 8.51 (d, 1H, J = 2.2 Hz), 8.22 (dd, 1H, J = 9.0, 2.3 Hz), 7.54 (d, 1H, J = 8.9 Hz), 7.13 (d, 2H, J = 8.9 Hz), 6.89 (d, 2H, J = 9.1 Hz), 4.26 (m, 1H), 3.79 (m, 1H), 2.32 (m, 2H), 2.20 (m, 2H) , 1.70 (m, 2H), 1.54 (m, 2H); 13 C NMR (DMSO- d 6 , 125 MHz) δ 169.9, 156.0, 154.4, 143.0, 143.0, 142.7, 129.1, 123.7, 123.2, 122.7, 121.7, 119.6, 117.8, 117.6, 117.5, 116.6, 2 94.6, 2 94.6, 2 94.6
32. 4-(((1,4-트랜스)-4-((6-32. 4-(((1,4-trans)-4-((6- 나이트로벤조[nitrobenzo[ dd ]티아졸]thiazole -2-일)아미노)-2-yl)amino) 사이클로헥실cyclohexyl )옥시)벤조나이트릴 [4-(((1,4-)oxy)benzonitrile [4-(((1,4- transtrans )-4-((6-)-4-((6- Nitrobenzo[Nitrobenzo[ dd ]thiazol]thiazol -2-yl)amino)cyclohexyl)oxy)benzonitrile] (화합물 32)-2-yl)amino)cyclohexyl)oxy)benzonitrile] (Compound 32)
2-클로로-6-나이트로벤조티아졸 (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤조나이트릴 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzonitrile; 70.5 mg, 0.33 mmol) 및 탄산칼륨 (K2CO3; 45.0 mg, 0.33 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 1시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:메탄올=10:1)에 의해 정제하여 27.3 mg (21 %)의 화합물 32를 노란색 고체로서 수득하였다.4-(((1,4-trans)-4-amino in DMF (1.5 mL) containing 2-chloro-6-nitrobenzothiazole (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol) Cyclohexyl)oxy)benzonitrile (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzonitrile; 70.5 mg, 0.33 mmol) and potassium carbonate (K 2 CO 3 ; 45.0 mg, 0.33 mmol) was added at ambient temperature. After stirring for 1 hour, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate:methanol=10:1) to give 27.3 mg (21%) of
1H NMR (DMSO-d 6, 500 MHz) δ 8.77 (s, 1H), 8.68 (m, 1H), 8.08 (m, 1H), 7.73 (m, 2H), 7.47 (dd, 1H, J = 8.8, 4.4 Hz), 7.14 (m, 2H), 4.53 (s, 1H), 3.87 (s, 1H), 2.10 (m, 4H), 1.53 (m, 4H); 13C NMR (DMSO-d 6, 125 MHz) δ 170.0, 161.0, 158.4, 140.7, 134.3, 131.0, 122.2, 119.3, 117.7, 117.1, 116.4, 102.5, 74.5, 52.3, 29.3, 29.2. 1 H NMR (DMSO- d 6 , 500 MHz) δ 8.77 (s, 1H), 8.68 (m, 1H), 8.08 (m, 1H), 7.73 (m, 2H), 7.47 (dd, 1H, J = 8.8 , 4.4 Hz), 7.14 (m, 2H), 4.53 (s, 1H), 3.87 (s, 1H), 2.10 (m, 4H), 1.53 (m, 4H); 13 C NMR (DMSO- d 6 , 125 MHz) δ 170.0, 161.0, 158.4, 140.7, 134.3, 131.0, 122.2, 119.3, 117.7, 117.1, 116.4, 102.5, 74.5, 52.3, 29.2, 29.3.
33. 6-나이트로-33. 6-Nitro- NN -- (( (1,4-트랜스)-4-(4-(1,4-trans)-4-(4- 나이트로페녹시nitrophenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [6-Nitro--2-Amine [6-Nitro- NN -((1,4--((1,4- transtrans )-4-(4-nitrophenoxy)cyclohexyl)benzo[)-4-(4-nitrophenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 33)]thiazol-2-amine] (Compound 33)
2-클로로-6-나이트로벤조티아졸 (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-nitrophenoxy)cyclohexan-1-amine; 77.0 mg, 0.33 mmol) 및 탄산칼륨 (K2CO3; 45.0 mg, 0.33 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 1시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:1)에 의해 정제하여 30.2 mg (22 %)의 화합물 33을 밝은 노란색 고체로서 수득하였다.(1,4-trans)-4-(4-nitro Phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-nitrophenoxy)cyclohexan-1-amine; 77.0 mg, 0.33 mmol) and potassium carbonate (K 2 CO 3 ; 45.0 mg, 0.33 mmol) was added at ambient temperature. After stirring for 1 hour, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:1) to give 30.2 mg (22%) of
1H NMR (DMSO-d 6, 500 MHz) δ 8.78 (d, 1H, J = 5.3 Hz), 8.69 (d, 1H, J = 1.2 Hz), 8.18 (d, 2H, J = 9.0 Hz), 8.09 (dd, 1H, J = 8.9, 1.8 Hz), 7.48 (d, 1H, J = 9.0 Hz), 7.19 (d, 2H, J = 9.0 Hz), 4.61 (m, 1H), 3.89 (m, 1H), 2.12 (m, 4H), 1.56 (m, 4H); 13C NMR (DMSO-d 6, 125 MHz) δ 170.0, 162.9, 158.4, 140.7, 140.6, 131.0, 126.0, 122.1, 117.7, 117.1, 115.8, 75.1, 52.2, 29.3, 29.1. 1 H NMR (DMSO- d 6 , 500 MHz) δ 8.78 (d, 1H, J = 5.3 Hz), 8.69 (d, 1H, J = 1.2 Hz), 8.18 (d, 2H, J = 9.0 Hz), 8.09 (dd, 1H, J = 8.9, 1.8 Hz), 7.48 (d, 1H, J = 9.0 Hz), 7.19 (d, 2H, J = 9.0 Hz), 4.61 (m, 1H), 3.89 (m, 1H) , 2.12 (m, 4H), 1.56 (m, 4H); 13 C NMR (DMSO- d 6 , 125 MHz) δ 170.0, 162.9, 158.4, 140.7, 140.6, 131.0, 126.0, 122.1, 117.7, 117.1, 115.8, 75.1, 52.2, 29.3, 29.1.
34. 34. NN -((1,4-트랜스)-4-(4-(-((1,4-trans)-4-(4-( 메틸술포닐methylsulfonyl )) 페녹시phenoxy )) 사이클로헥실cyclohexyl )-6-)-6- 나이트로벤조[nitrobenzo[ dd ]티아졸]thiazole -2-아민 [-2-amine [ NN -((1,4--((1,4- transtrans )-4-(4-()-4-(4-( MethylsulfonylMethylsulfonyl )) phenoxyphenoxy )) cyclohexylcyclohexyl )-6-nitrobenzo[)-6-nitrobenzo[ dd ]thiazol-2-amine] (화합물 34)]thiazol-2-amine] (Compound 34)
2-클로로-6-나이트로벤조티아졸 (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 87.9 mg, 0.33 mmol) 및 탄산칼륨 (K2CO3; 45.0 mg, 0.33 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 1시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=3:1)에 의해 정제하여 68.4 mg (47 %)의 화합물 34를 노란색 고체로서 수득하였다.(1,4-trans)-4-(4-(methyl) in DMF (1.5 mL) containing 2-chloro-6-nitrobenzothiazole (70.0 mg, 0.33 mmol) Sulfonyl)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 87.9 mg, 0.33 mmol) and potassium carbonate (K 2 CO 3 ; 45.0 mg, 0.33 mmol) was added at ambient temperature. After stirring for 1 hour, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=3:1) to give 68.4 mg (47%) of
1H NMR (DMSO-d 6, 500 MHz) δ 8.78 (s, 1H), 8.68 (d, 1H, J = 2.2 Hz), 8.09 (dd, 1H, J = 8.9, 2.4 Hz), 7.82 (d, 2H, J = 8.8 Hz), 7.47 (d, 1H, J = 8.9 Hz), 7.19 (d, 2H, J = 8.9 Hz), 4.55 (m, 1H), 3.88 (m, 1H), 3.15 (s, 3H), 2.12 (m, 4H), 1.55 (m, 4H); 13C NMR (DMSO-d 6, 125 MHz) δ 170.0, 161.3, 158.4, 140.7, 132.3, 131.0, 129.3, 122.1, 117.7, 117.1, 115.8, 74.5, 52.3, 44.0, 29.3, 29.1. 1 H NMR (DMSO- d 6 , 500 MHz) δ 8.78 (s, 1H), 8.68 (d, 1H, J = 2.2 Hz), 8.09 (dd, 1H, J = 8.9, 2.4 Hz), 7.82 (d, 2H, J = 8.8 Hz), 7.47 (d, 1H, J = 8.9 Hz), 7.19 (d, 2H, J = 8.9 Hz), 4.55 (m, 1H), 3.88 (m, 1H), 3.15 (s, 3H), 2.12 (m, 4H), 1.55 (m, 4H); 13 C NMR (DMSO- d 6 , 125 MHz) δ 170.0, 161.3, 158.4, 140.7, 132.3, 131.0, 129.3, 122.1, 117.7, 117.1, 115.8, 74.5, 52.3, 44.0, 29.1, 29.1.
35. 4-(((1,4-트랜스)-4-((6-35. 4-(((1,4-trans)-4-((6- 나이트로벤조[nitrobenzo[ dd ]티아졸]thiazole -2-일)아미노)-2-yl)amino) 사이클로헥실cyclohexyl )옥시)벤젠술폰아마이드 [4-(((1,4-)oxy)benzenesulfonamide [4-(((1,4- transtrans )-4-((6-)-4-((6- Nitrobenzo[Nitrobenzo[ dd ]thiazol]thiazol -2-yl)amino)cyclohexyl)oxy)benzenesulfonamide] (화합물 35)-2-yl) amino) cyclohexyl) oxy) benzenesulfonamide] (Compound 35)
2-클로로-6-나이트로벤조티아졸 (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤젠술폰아마이드 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzenesulfonamide; 88.1 mg, 0.33 mmol) 및 탄산칼륨 (K2CO3; 45.0 mg, 0.33 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=2:1)에 의해 정제하여 26.8 mg (18 %)의 화합물 35를 노란색 고체로서 수득하였다.4-(((1,4-trans)-4-amino in DMF (1.5 mL) containing 2-chloro-6-nitrobenzothiazole (2-chloro-6-nitrobenzothiazole; 70.0 mg, 0.33 mmol) Cyclohexyl)oxy)benzenesulfonamide (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzenesulfonamide; 88.1 mg, 0.33 mmol) and potassium carbonate (K 2 CO 3 ; 45.0 mg, 0.33 mmol) was added at ambient temperature. After stirring for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=2:1) to give 26.8 mg (18%) of
1H NMR (DMSO-d 6, 500 MHz) δ 8.77 (d, 1H, J = 6.1 Hz), 8.69 (d, 1H, J = 2.4 Hz), 8.09 (dd, 1H, J = 8.9, 2.5 Hz), 7.73 (d, 2H, J = 8.9 Hz), 7.48 (d, 1H, J = 9.0 Hz), 7.19 (s, 2H), 7.12 (d, 2H, J = 8.9 Hz), 4.51 (m, 1H), 3.88 (s, 1H), 2.11 (m, 4H), 1.54 (m, 4H); 13C NMR (DMSO-d 6, 125 MHz) δ 170.0, 159.9, 158.4, 140.7, 136.0, 131.0, 127.8, 122.2, 117.7, 117.1, 115.4, 74.3, 52.3, 40.0, 29.3, 29.2. 1 H NMR (DMSO- d 6 , 500 MHz) δ 8.77 (d, 1H, J = 6.1 Hz), 8.69 (d, 1H, J = 2.4 Hz), 8.09 (dd, 1H, J = 8.9, 2.5 Hz) , 7.73 (d, 2H, J = 8.9 Hz), 7.48 (d, 1H, J = 9.0 Hz), 7.19 (s, 2H), 7.12 (d, 2H, J = 8.9 Hz), 4.51 (m, 1H) , 3.88 (s, 1H), 2.11 (m, 4H), 1.54 (m, 4H); 13 C NMR (DMSO- d 6 , 125 MHz) δ 170.0, 159.9, 158.4, 140.7, 136.0, 131.0, 127.8, 122.2, 117.7, 117.1, 115.4, 74.3, 52.3, 40.0, 29.3, 29.2.
36. 6-36. 6- 메톡시methoxy -- NN -((1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥실)벤조[-((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]티아졸-2-아민 [6-]Thiazol-2-amine [6- MethoxyMethoxy -- NN -((1,4--((1,4- transtrans )-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[)-4-(4-(trifluoromethyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 36)]thiazol-2-amine] (Compound 36)
2-클로로-6-메톡시벤조티아졸 (2-chloro-6-methoxybenzothiazole; 50.0 mg, 0.25 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(트리플루오로메틸)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 64.8 mg, 0.25 mmol) 및 탄산칼륨 (K2CO3; 34.6 mg, 0.25 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 140 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:3)에 의해 정제하여 18.3 mg (17 %)의 화합물 36을 아이보리색 고체로서 수득하였다.(1,4-trans)-4-(4-(tri) in DMF (1.5 mL) containing 2-chloro-6-methoxybenzothiazole (50.0 mg, 0.25 mmol) Fluoromethyl)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(trifluoromethyl)phenoxy)cyclohexan-1-amine; 64.8 mg, 0.25 mmol) and potassium carbonate (K 2 CO 3 ; 34.6 mg, 0.25 mmol) was added at ambient temperature. After stirring at 140 °C for 17 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:3) to give 18.3 mg (17%) of
1H NMR (CDCl3, 500 MHz) δ 7.53 (d, 2H, J = 8.6 Hz), 7.44 (d, 1H, J = 8.8 Hz), 7.13 (d, 1H, J = 2.2 Hz), 6.94 (d, 2H, J = 8.6 Hz), 6.90 (dd, 1H, J = 8.8, 2.5 Hz), 4.31 (m, 1H), 3.82 (s, 3H), 3.70 (m, 1H), 2.30 (m, 2H), 2.17 (m, 2H), 1.68 (m, 2H), 1.46 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 165.1, 160.2, 155.4, 146.0, 131.0, 127.8, 127.1, 125.6, 123.5, 123.3, 123.1, 122.8, 122.5, 121.3, 119.2, 115.7, 113.7, 105.7, 74.8, 56.0, 53.4, 30.3, 29.7. 1 H NMR (CDCl 3 , 500 MHz) δ 7.53 (d, 2H, J = 8.6 Hz), 7.44 (d, 1H, J = 8.8 Hz), 7.13 (d, 1H, J = 2.2 Hz), 6.94 (d , 2H, J = 8.6 Hz), 6.90 (dd, 1H, J = 8.8, 2.5 Hz), 4.31 (m, 1H), 3.82 (s, 3H), 3.70 (m, 1H), 2.30 (m, 2H) , 2.17 (m, 2H), 1.68 (m, 2H), 1.46 (m, 2H); 13 C NMR (CDCL 3 , 125 MHz) Δ 165.1, 160.2, 155.4, 146.0, 131.0, 127.8, 127.1, 125.6, 123.5, 123.3, 123.1, 122.8, 122.5, 121.3, 119.2, 115.7, 113.7, 105.7, 74.8, 56.0, 56.0 , 53.4, 30.3, 29.7.
37. 4-(((1,4-트랜스)-4-((6-37. 4-(((1,4-trans)-4-((6- 메톡시벤조[methoxybenzo[ dd ]티아졸]thiazole -2-일)아미노)-2-yl)amino) 사이클로헥실cyclohexyl )옥시)벤조나이트릴 [4-(((1,4-)oxy)benzonitrile [4-(((1,4- transtrans )-4-((6-)-4-((6- Methoxybenzo[Methoxybenzo[ dd ]thiazol]thiazol -2-yl)amino)cyclohexyl)oxy)benzonitrile] (화합물 37)-2-yl)amino)cyclohexyl)oxy)benzonitrile] (Compound 37)
2-클로로-6-메톡시벤조티아졸 (2-chloro-6-methoxybenzothiazole; 70.0 mg, 0.35 mmol)이 함유된 DMF (1.5 mL)에 4-(((1,4-트랜스)-4-아미노사이클로헥실)옥시)벤조나이트릴 (4-(((1,4-trans)-4-aminocyclohexyl)oxy)benzonitrile; 83.4 mg, 0.39 mmol) 및 탄산칼륨 (K2CO3; 48.4 mg, 0.35 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 140 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:2)에 의해 정제하여 35.9 mg (27 %)의 화합물 37을 아이보리색 고체로서 수득하였다.4-(((1,4-trans)-4-amino in DMF (1.5 mL) containing 2-chloro-6-methoxybenzothiazole (70.0 mg, 0.35 mmol) Cyclohexyl)oxy)benzonitrile (4-(((1,4- trans )-4-aminocyclohexyl)oxy)benzonitrile; 83.4 mg, 0.39 mmol) and potassium carbonate (K 2 CO 3 ; 48.4 mg, 0.35 mmol) was added at ambient temperature. After stirring at 140 °C for 17 h, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:2) to give 35.9 mg (27%) of
1H NMR (CDCl3, 500 MHz) δ 7.57 (d, 2H, J = 8.8 Hz), 7,44 (d, 1H, J = 8.8 Hz), 7.13 (d, 1H, J = 2.3 Hz), 6.93 (d, 2H, J = 8.8 Hz), 6.90 (m, 1H), 5.51 (s, 1H), 4.34 (m, 1H), 3.82 (s, 3H), 3.73 (m, 1H), 2.31 (m, 2H), 2.17 (m, 2H), 1.70 (m, 2H), 1.47 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 164.8, 161.1, 155.5, 145.6, 134.2, 130.9, 119.4, 119.2, 116.2, 113.8, 105.7, 103.9, 74.9, 56.0, 53.2, 30.2, 29.5. 1 H NMR (CDCl 3 , 500 MHz) δ 7.57 (d, 2H, J = 8.8 Hz), 7,44 (d, 1H, J = 8.8 Hz), 7.13 (d, 1H, J = 2.3 Hz), 6.93 (d, 2H, J = 8.8 Hz), 6.90 (m, 1H), 5.51 (s, 1H), 4.34 (m, 1H), 3.82 (s, 3H), 3.73 (m, 1H), 2.31 (m, 2H), 2.17 (m, 2H), 1.70 (m, 2H), 1.47 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 164.8, 161.1, 155.5, 145.6, 134.2, 130.9, 119.4, 119.2, 116.2, 113.8, 105.7, 103.9, 74.9, 56.0, 53.2, 30.5.2, 30.5.2
38. 6-38. 6- 메톡시methoxy -- NN -- (( (1,4-트랜스)-4-(4-(1,4-trans)-4-(4- 나이트로페녹시nitrophenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [6--2-amine [6- MethoxyMethoxy -- NN -((1,4--((1,4- transtrans )-4-(4-nitrophenoxy)cyclohexyl)benzo[)-4-(4-nitrophenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 38)]thiazol-2-amine] (Compound 38)
2-클로로-6-메톡시벤조티아졸 (2-chloro-6-methoxybenzothiazole; 70.0 mg, 0.35 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-나이트로페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-nitrophenoxy)cyclohexan-1-amine; 124.0 mg, 0.53 mmol) 및 탄산칼륨 (K2CO3; 96.8 mg, 0.70 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=1:1)에 의해 정제하여 16.1 mg (12 %)의 화합물 38을 아이보리색 고체로서 수득하였다.(1,4-trans)-4-(4-nitro Phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-nitrophenoxy)cyclohexan-1-amine; 124.0 mg, 0.53 mmol) and potassium carbonate (K 2 CO 3 ; 96.8 mg, 0.70 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate: n -hexane=1:1) to give 16.1 mg (12%) of
1H NMR (CDCl3, 500 MHz) δ 8.18 (d, 2H, J = 8.5 Hz), 7.44 (d, 1H, J = 8.7 Hz), 7.13 (s, 1H), 6.93 (d, 2H, J = 8.9 Hz), 6.90 (m, 1H), 5.45 (s, 1H), 4.38 (m, 1H), 3.82 (s, 3H), 3.74 (m, 1H), 2.32 (m, 2H), 2.19 (m, 2H), 1.71 (m, 2H), 1.48 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 164.8, 162.9, 155.5, 145.7, 141.4, 131.0, 126.1, 119.2, 115.4, 113.7, 105.7, 75.4, 56.0, 53.2, 30.2, 29.6. 1 H NMR (CDCl 3 , 500 MHz) δ 8.18 (d, 2H, J = 8.5 Hz), 7.44 (d, 1H, J = 8.7 Hz), 7.13 (s, 1H), 6.93 (d, 2H, J = 8.9 Hz), 6.90 (m, 1H), 5.45 (s, 1H), 4.38 (m, 1H), 3.82 (s, 3H), 3.74 (m, 1H), 2.32 (m, 2H), 2.19 (m, 2H), 1.71 (m, 2H), 1.48 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 164.8, 162.9, 155.5, 145.7, 141.4, 131.0, 126.1, 119.2, 115.4, 113.7, 105.7, 75.4, 56.0, 53.2, 30.6.2, 29.6.2
39. 6-39. 6- 메톡시methoxy -- NN -- (( (1,4-트랜스)-4-(4-((1,4-trans)-4-(4-( 메틸술포닐methylsulfonyl )) 페녹시phenoxy )) 사이클로헥실cyclohexyl )) 벤조[benzo[ dd ]티아졸]thiazole -2-아민 [6--2-amine [6- MethoxyMethoxy -- NN -((1,4--((1,4- transtrans )-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[)-4-(4-(methylsulfonyl)phenoxy)cyclohexyl)benzo[ dd ]thiazol-2-amine] (화합물 39)]thiazol-2-amine] (Compound 39)
2-클로로-6-메톡시벤조티아졸 (2-chloro-6-methoxybenzothiazole; 70.0 mg, 0.35 mmol)이 함유된 DMF (1.5 mL)에 (1,4-트랜스)-4-(4-(메틸술포닐)페녹시)사이클로헥산-1-아민 ((1,4-trans)-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 141.0 mg, 0.53 mmol) 및 탄산칼륨 (K2CO3; 72.6 mg, 0.53 mmol)을 주위 온도 (ambient temperature)에서 추가했다. 120 ℃에서 17시간 동안 교반한 후, 상기 혼합물을 물로 퀀칭 (quenching)시키고, 에틸아세테이트 (EtOAc)로 추출했다. 그 후, 합쳐진 유기층을 MgSO4상에서 건조시키고 진공에서 농축시켰다. 잔류물을 실리카겔에서 플래시 컬럼 크로마토그래피 (에틸아세테이트:n-헥산=2:1)에 의해 정제하여 39.8 mg (26 %)의 화합물 39를 흰색 고체로서 수득하였다.(1,4-trans)-4-(4-(methyl) in DMF (1.5 mL) containing 2-chloro-6-methoxybenzothiazole (70.0 mg, 0.35 mmol) Sulfonyl)phenoxy)cyclohexan-1-amine ((1,4- trans )-4-(4-(methylsulfonyl)phenoxy)cyclohexan-1-amine; 141.0 mg, 0.53 mmol) and potassium carbonate (K 2 CO 3 ; 72.6 mg, 0.53 mmol) was added at ambient temperature. After stirring at 120 °C for 17 hours, the mixture was quenched with water and extracted with ethyl acetate (EtOAc). The combined organic layers were then dried over MgSO 4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate:n-hexane=2:1) to give 39.8 mg (26%) of
1H NMR (CDCl3, 500 MHz) δ 7.85 (d, 2H, J = 8.9 Hz), 7.43 (d, 1H, J = 8.8 Hz), 7.12 (d, 1H, J = 2.5 Hz), 7.00 (d, 2H, J = 8.9 Hz), 6.90 (dd, 1H, J = 8.8, 2.6 Hz), 4.37 (m, 1H), 3.82 (s, 3H), 3.73 (m, 1H), 3.03 (s, 3H), 2.31 (m, 2H), 2.18 (m, 2H), 1.70 (m, 2H), 1.49 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 164.9, 162.0, 155.5, 145.4, 132.2, 130.8, 129.7, 119.1, 116.0, 113.8, 105.7, 75.0, 56.0, 53.3, 45.0, 30.1, 29.5. 1 H NMR (CDCl 3 , 500 MHz) δ 7.85 (d, 2H, J = 8.9 Hz), 7.43 (d, 1H, J = 8.8 Hz), 7.12 (d, 1H, J = 2.5 Hz), 7.00 (d , 2H, J = 8.9 Hz), 6.90 (dd, 1H, J = 8.8, 2.6 Hz), 4.37 (m, 1H), 3.82 (s, 3H), 3.73 (m, 1H), 3.03 (s, 3H) , 2.31 (m, 2H), 2.18 (m, 2H), 1.70 (m, 2H), 1.49 (m, 2H); 13 C NMR (CDCl 3 , 125 MHz) δ 164.9, 162.0, 155.5, 145.4, 132.2, 130.8, 129.7, 119.1, 116.0, 113.8, 105.7, 75.0, 56.0, 53.3, 45.0, 29.5.0, 30.5.0, 30.5.0
[[ 실시예Example 1] One] NN -(4--(4- 아릴옥시사이클로헥실aryloxycyclohexyl )) 벤조티아졸benzothiazole -2--2- 아민amine ( ( NN -(4-aryloxycyclohexyl)benzothiazole-2-amine) 유도체들에 대한 -(4-aryloxycyclohexyl)benzothiazole-2-amine) derivatives eIF2αeIF2α 인산화의 배수 변화 분석 Analysis of fold change in phosphorylation
Cell signaling 사의 Pathscan phospho-eIF2α (Ser51) Sandwich ELISA Kit #7286를 사용하였다. K562 세포주를 37℃ 및 5% CO2에서 serum-free RPMI 배지에서 배양하였다. 세포에 10 μM의 농도로 상기 화합물 1 내지 36을 처리하였다. 화합물 처리 후 6시간 뒤에 키트에 동봉된 lysis buffer로 세포를 lysis하여 50 μg의 단백질을 정량하여 얻었다. 그 이후 manufacturer's protocol에 따라 ELISA assay를 진행하여 흡광도를 얻었다. 얻어진 각각의 화합물에 대한 흡광도는 control (DMSO-treated)을 1로 둔 값에 표준화되었다. 결과는 표 1과 같다.Pathscan from Cell Signaling The phospho-eIF2α (Ser51) Sandwich ELISA Kit #7286 was used. The K562 cell line was cultured in serum-free RPMI medium at 37°C and 5% CO 2 . Cells were treated with
[[ 실시예Example 2] K562에 대한 2] for K562 NN -(4--(4- 아릴옥시사이클로헥실aryloxycyclohexyl )) 벤조티아졸benzothiazole -2--2- 아민amine ( ( NN -(4-aryloxycyclohexyl)benzothiazole-2-amine) 유도체들의 항-증식 활성 분석Analysis of anti-proliferative activity of -(4-aryloxycyclohexyl)benzothiazole-2-amine) derivatives
CCK-8 assay (cell counting kit-8 assay, Dojindo, Kumamoto, Japan)을 수행하였다. K562 세포주를 37℃ 및 5% CO2에서 10% FBS와 1% ABAM이 첨가된 RPMI 배지에서 배양하였다. 세포에 각각 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM 농도의 상기 화합물 1, 13, 14, 19 내지 30, 32, 34 및 36을 처리하였다. 3일 동안 배양한 후, 10 μL의 CCK-8 solution을 처리한 후, 4시간 배양하였다. 그 후, 450 nm에서의 흡광도를 측정하여 각각의 화합물의 IC50 value를 구하였다. 결과는 표 2와 같다.CCK-8 assay (cell counting kit-8 assay, Dojindo, Kumamoto, Japan) was performed. The K562 cell line was cultured in RPMI medium supplemented with 10% FBS and 1% ABAM at 37°C and 5% CO 2 . Cells were treated with
이상으로 본 발명의 특정한 부분을 상세히 기술한 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described specific parts of the present invention in detail above, it is clear that these specific techniques are only preferred embodiments for those skilled in the art, and the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (12)
[화학식 1]
상기 화학식 1에서,
R1 및 R2는 각각 동일하거나 다를 수 있고, 수소 (H), 할로겐, 트리플루오로메틸 (CF3), 나이트로 (NO2), (C1~C4)알콕시, 트리플루오로메톡시 (OCF3), 시아노 (CN), 나이트로 (NO2), (C1~C4)알킬술포닐 및 아미노술포닐 (SO2NH2)로 이루어진 군에서 선택됨.A compound selected from a 2-aminobenzothiazole derivative compound represented by Formula 1 below, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof:
[Formula 1]
In Formula 1,
R 1 and R 2 may each be the same or different, and hydrogen (H), halogen, trifluoromethyl (CF 3 ), nitro (NO 2 ), (C1~C4) alkoxy, trifluoromethoxy (OCF 3 ), cyano (CN), nitro (NO 2 ), (C1-C4) alkylsulfonyl and aminosulfonyl (SO 2 NH 2 ).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2022/013755 WO2023043208A1 (en) | 2021-09-15 | 2022-09-15 | Novel 2-aminobenzothiazole derivative and preparation method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210122948 | 2021-09-15 | ||
KR1020210122948 | 2021-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230040292A true KR20230040292A (en) | 2023-03-22 |
Family
ID=86005698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220115668A KR20230040292A (en) | 2021-09-15 | 2022-09-14 | Novel 2-aminobenzothiazole derivatives and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230040292A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102252540B1 (en) | 2016-11-16 | 2021-05-13 | 경북대학교 산학협력단 | Ligand-metal complexes conjugated with benzothiazole derivatives and method for preparing it |
-
2022
- 2022-09-14 KR KR1020220115668A patent/KR20230040292A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102252540B1 (en) | 2016-11-16 | 2021-05-13 | 경북대학교 산학협력단 | Ligand-metal complexes conjugated with benzothiazole derivatives and method for preparing it |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9562060B2 (en) | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | |
CN112689633A (en) | For inhibiting Nav1.8 pyridine carboxamide Compounds | |
CA2787121C (en) | Aminopyridine derivatives as anti-malarial agents | |
CN108136044A (en) | Based on imido proteolysis conditioning agent and associated method of use | |
CN106866571B (en) | Heterocyclic urea compound and its pharmaceutical composition and application | |
KR20210019119A (en) | Pyridazine (PYRIDAZINE) compounds to inhibit Nav1.8 | |
KR101789430B1 (en) | Novel compound having SMO-inhibitory activity and composition for preventing or treating cancer comprising the same as an active ingredient | |
KR101364658B1 (en) | Novel purinylpyridinylamino-2,4-difluorophenyl sulfoneamide derivatives, phamaceutically acceptable salt thereof, preparation method thereof and phamaceutical composition for inhibiting Raf kinase activity | |
MX2014012916A (en) | Amide derivatives as ttx-s blockers. | |
JP2012514019A (en) | Toluidinesulfonamides and their use as inhibitors | |
KR20230040292A (en) | Novel 2-aminobenzothiazole derivatives and preparation method thereof | |
KR100916160B1 (en) | Pharmaceutical Compositions for Treating or Preventing Cancer | |
CN108473504B (en) | Novel dihydropyranopyrimidinone derivatives and uses thereof | |
KR20220162680A (en) | Novel squaramide derivatives and use thereof | |
AU2022251900A9 (en) | Composition for preventing or treating neurodegenerative disease comprising compound inducing expression of anti-aging gene klotho | |
US20230172908A1 (en) | Composition containing 1h-pyrazole-3-amide-based compound derivative for prevention or treatment of fibrosis | |
JP2014528464A (en) | 2-Carboxamide cycloaminourea derivatives in combination with HSP90 inhibitors for the treatment of proliferative diseases | |
KR101948555B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising receptor tyrosine kinases inhibitor | |
KR102530601B1 (en) | Novel compounds that induces the expression of anti-aging gene klotho | |
KR20200056685A (en) | Novel picolinimidamide compound and composition for preventing or treating diabetes comprising the same | |
WO2023043208A1 (en) | Novel 2-aminobenzothiazole derivative and preparation method therefor | |
KR102432841B1 (en) | Substituted arylurea compounds for inducing apoptosis and composition for anticancer comprising the same | |
KR102231354B1 (en) | Composition for protecting ocular nerve containing chalcone derivates | |
KR101643306B1 (en) | Novel quinoxaline derivatives and use thereof | |
KR102426016B1 (en) | Novel 1-phenyl-1H-pyrazole derivatives and use thereof |